Intratumoral vaccination

ABSTRACT

The present disclosure relates to, inter alia, a method for treating a tumor by intratumorally delivering an effective amount of a composition comprising an expression vector that comprises a first nucleotide sequence encoding a secretable vaccine protein, and a second nucleotide sequence encoding a T cell costimulatory fusion protein.

RELATED APPLICATIONS

This application claims priority to and the benefit of U.S. ProvisionalPat. Application No. 62/481,219, filed on Apr. 4, 2017, and U.S. Pat.Provisional Pat. Application No. 62/599,458, filed on Dec. 15, 2017, thecontents of each of which are incorporated herein by reference in theirentireties.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

The contents of the text file name “HTB-024PC_SequenceListing_ST25”,which was created on Mar. 21, 2018 and is 70 KB in size, are herebyincorporated herein by reference in their entirety.

FIELD

This document relates, inter alia, to materials and methods for usingvaccination and T-cell co-stimulation to treat a clinical condition in asubject.

BACKGROUND

Most cancer immunotherapies (IT) have a higher likelihood of succeedingif the targeted tumor has a preexisting state of inflammation elicitedby the combined presentation of shared- and neo-antigens from tumorcells. Thus, novel combination treatment modalities are needed toconvert non-immunogenic, ‘cold’ tumors into inflamed ‘hot’ tumors.

Gp96-Ig/Fc-OX40L is a re-engineered molecular chaperone, designed toexport and deliver MHC I-associated antigens to APCs in context of theimmune costimulator, OX40L. Allogeneic cancer vaccine cell linesdesigned to co-secrete Gp96-Ig and Fc-OX40L, generate antigen-specificCD4+/CD8+ anti-tumor responses in both highly immunogenic (CT26) andless immunogenic (B16) mouse tumors (Fromm et al., Cancer Immunol Res,2016). Such a strategy allows for Gp96-Ig-mediated chaperoning ofantigens from the allogeneic vaccine cell line (shared antigens), whichcould benefit further from increased presentation of tumor-derivedpeptides (neo-antigens) that are only accessible if Gp96-Ig/Fc-OX40L isexpressed from within the tumor.

SUMMARY

Accordingly, in some aspects, the present invention relates to a methodfor treating a tumor in a subject in need thereof, comprisingintratumorally delivering an effective amount of a compositioncomprising an expression vector that comprises a nucleotide sequenceencoding a secretable vaccine protein (e.g., without limitationgp96-Ig).

In some aspects, the present invention relates to a method for treatinga tumor in a subject in need thereof, comprising intratumorallydelivering an effective amount of a composition comprising a firstnucleotide sequence encoding a secretable vaccine protein (e.g., withoutlimitation gp96-Ig), and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40), optionally on a single expressionvector. In various embodiments, the intratumoral delivery is in vivo byinjection.

In aspects, the present invention relates to a method for treating atumor in a subject in need thereof, comprising administering to asubject in need thereof a combination therapy of (1) intratumorallydelivery of an effective amount of a composition comprising anexpression vector that comprises a nucleotide sequence encoding asecretable vaccine protein (e.g., without limitation gp96-Ig), and (2)an effective amount of a biological cell comprising an expression vectorthat comprises a nucleotide sequence encoding a secretable vaccineprotein (e.g., without limitation gp96-Ig).

In other aspects, the present invention relates to a method for treatinga tumor in a subject in need thereof, comprising administering to asubject in need thereof a combination therapy of (1) intratumorallydelivery of an effective amount of a composition comprising a firstnucleotide sequence encoding a secretable vaccine protein (e.g., withoutlimitation gp96-Ig), and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40) and (2) an effective amount of abiological cell comprising an expression vector that comprises a firstnucleotide sequence encoding a secretable vaccine protein (e.g., withoutlimitation gp96-Ig), and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40), wherein the T cell costimulatoryfusion protein enhances activation of antigen-specific T cells whenadministered to the subject.

In other aspects, the present invention relates to a method for treatinga tumor in a subject in need thereof, comprising administering to asubject in need thereof a combination therapy of (1) intratumorallydelivery of an effective amount of a composition comprising anexpression vector that comprises a first nucleotide sequence encoding asecretable vaccine protein (e.g., without limitation gp96-Ig), and asecond nucleotide sequence encoding a T cell costimulatory fusionprotein (e.g., without limitation OX40L-Ig, or a portion thereof thatbinds to OX40) and (2) an effective amount of a biological cellcomprising an expression vector that comprises a first nucleotidesequence encoding a secretable vaccine protein (e.g., without limitationgp96-Ig), and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40), wherein the T cell costimulatoryfusion protein enhances activation of antigen-specific T cells whenadministered to the subject.

Accordingly, in various aspects, direct intratumoral administration(i.e., in vivo, e.g., by injection into a tumor -e.g., in a primary orsecondary tumor (e.g., metastatic lesion)) of an expression vectorencoding a secretable vaccine protein (e.g., without limitation gp96-Ig)is paired with administration of a biological cell that has beenmanipulated (e.g., ex vivo) to comprise an expression vector encoding asecretable vaccine protein (e.g., without limitation gp96-Ig).

In various aspects, direct intratumoral administration (i.e., in vivo,e.g., by injection into a tumor - e.g., in a primary or secondary tumor(e.g., metastatic lesion)) of an expression vector encoding a secretablevaccine protein (e.g., without limitation gp96-Ig), and a secondnucleotide sequence encoding a T cell costimulatory fusion protein ispaired with administration of a biological cell that has beenmanipulated (e.g., ex vivo) to comprise an expression vector encoding asecretable vaccine protein (e.g., without limitation gp96-Ig), and asecond nucleotide sequence encoding a T cell costimulatory fusionprotein. In various embodiments, the T cell costimulatory fusion proteinused in the intratumoral administration is the same as the T cellcostimulatory fusion protein of the biological cell. In variousembodiments, the T cell costimulatory fusion protein used in theintratumoral administration is different than the T cell costimulatoryfusion protein of the biological cell.

In various embodiments, the present methods elicit a potent immuneresponse in less-immunogenic tumors, optional a tumor with reducedinflammation (“cold tumor”) relative to a responsive, inflamed tumor(“hot tumor”).

In various embodiments, the present methods enhance CD4+/CD8+ T cellcross-priming to tumor neo-antigens.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic of the present studies.

FIGS. 2A-C shows optimization of electroporation (EP) conditions forGp96-Ig/Fc-OX40L DNA delivery into B16.F10-ova melanoma tumors. FIG. 2Ashows the electroporation parameters. FIG. 2B is a bar graph that showsGP96-Ig mRNA levels in the tumor. The left bar (No EP), the middle bar(300 V/cm) and right bar (1500 V/cm) conditions. FIG. 2C is a bar graphthat shows tumor lysate associated OX40L protein was quantified by qPCRand ELISA, respectively. The left bar (No EP), the middle bar (300 V/cm)and right bar (1500 V/cm) conditions.

FIGS. 3A-F shows intratumoral EP of Gp96-Ig/Fc-OX40L DNA alone leads toCD8 T cell cross priming and delayed tumor growth. FIG. 3A shows theexperimental design. FIG. 3B shows treated tumor size postelectroporation, at day 0, lines denote tumor size of 200 mm² for EPonly, at day 10 lines denote tumor size of 300 mm² for EP only and atdays 30 to 40 lines denote tumor size of 200 mm² for GP96-Ig/Fc-OX40L +EP. FIG. 3C shows untreated tumor size days’ post electroporation, atday 0 lines denote tumor size of 200 mm² for EP only. FIG. 3D showsOva-antigen specific CD8+ T cell expansion. FIG. 3E shows Ova-antigenspecific memory precursor CD8 cells (EP only on left, Gp96-Ig/Fc-OX40L +EP on right). FIG. 3F shows an overall survival plot days’ post primarytumor inoculation, day 32 shows percent survival for EP only and day 40shows percent survival for GP96-lg/Fc-OX40L + EP (for reference, at day30, the top curve is Gp96-Ig/Fc-OX40L + EP and the bottom curve is EPonly.

FIGS. 4A-F shows combination of intratumoral EP and allogeneicvaccination of Gp96-Ig/Fc-OX40L leads to increased expansion of CD8 Tcell cross priming and improved anti-tumor response. FIG. 4A shows theexperimental design. FIG. 4B shows treated tumor area on day 16 posttumor inoculation. FIG. 4C shows untreated tumor area on day 13 posttumor inoculation. FIG. 4D shows overall survival in untreated, Vaccinecontrol, Gp96-Ig/Fc-OX40L EP only, Gp96-Ig/Fc-OX40L +Vaccine only andEP+ Vaccine Combo. FIG. 4E shows total CD8 T cells in tumor, (◆)Notreatment, (●)Vaccine control, (∇) EP, (⊕) Vaccine, and (Φ) EP + VaccineCombo. FIG. 4F shows tetramer positive CD8 T cells in tumor, (◆)Notreatment, (●)Vaccine control, (∇) EP, (⊕) Vaccine, and (Φ) EP + VaccineCombo.

DETAILED DESCRIPTION

Accordingly, in some aspects, the present invention relates to a methodfor treating a tumor in a subject in need thereof, comprisingintratumorally delivering an effective amount of a compositioncomprising an expression vector that comprises a nucleotide sequenceencoding a secretable vaccine protein (e.g., without limitationgp96-Ig).

In some aspects, the present invention relates to a method for treatinga tumor in a subject in need thereof, comprising intratumorallydelivering an effective amount of a composition comprising an expressionvector that comprises a first nucleotide sequence encoding a secretablevaccine protein (e.g., without limitation gp96-Ig), and a secondnucleotide sequence encoding a T cell costimulatory fusion protein(e.g., without limitation OX40L-Ig, or a portion thereof that binds toOX40). In various embodiments, the intratumoral delivery is in vivo byinjection.

In other aspects, the present invention relates to a method for treatinga tumor in a subject in need thereof, comprising administering to asubject in need thereof a combination therapy of (1) intratumorallydelivery of an effective amount of a composition comprising anexpression vector that comprises a nucleotide sequence encoding asecretable vaccine protein (e.g., without limitation gp96-Ig), and (2)an effective amount of a biological cell comprising an expression vectorthat comprises a nucleotide sequence encoding a secretable vaccineprotein (e.g., without limitation gp96-Ig).

In other aspects, the present invention relates to a method for treatinga tumor in a subject in need thereof, comprising administering to asubject in need thereof a combination therapy of (1) intratumorallydelivery of an effective amount of a composition comprising anexpression vector that comprises a first nucleotide sequence encoding asecretable vaccine protein (e.g., without limitation gp96-Ig), and asecond nucleotide sequence encoding a T cell costimulatory fusionprotein (e.g., without limitation OX40L-Ig, or a portion thereof thatbinds to OX40) and (2) an effective amount of a biological cellcomprising an expression vector that comprises a first nucleotidesequence encoding a secretable vaccine protein (e.g., without limitationgp96-Ig), and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40), wherein the T cell costimulatoryfusion protein enhances activation of antigen-specific T cells whenadministered to the subject

In various embodiments, the present methods elicit a potent immuneresponse in less-immunogenic tumors, optional a tumor with reducedinflammation (“cold tumor”) relative to a responsive, inflamed tumor(“hot tumor”).

In various embodiments, the present methods enhance CD4+/CD8+ T cellcross-priming to tumor neo-antigens.

Vaccine Proteins

Vaccine proteins can induce immune responses that find use in thepresent invention. In various embodiments, the present inventionprovides expression vectors comprising a nucleotide sequence that encodea secretable vaccine protein. In various embodiments, the presentinvention provides expression vectors comprising a first nucleotidesequence that encode a secretable vaccine protein and a secondnucleotide sequence that encode a T cell costimulatory fusion protein.Compositions comprising the expression vectors of the present inventionare also provided. In various embodiments, such compositions areutilized in methods of treating subjects to stimulate immune responsesin the subject including enhancing the activation of antigen-specific Tcells in the subject. The present compositions find use in the treatmentof various diseases including cancer.

The heat shock protein (hsp) gp96, localized in the endoplasmicreticulum (ER), serves as a chaperone for peptides on their way to MHCclass I and II molecules. Gp96 obtained from tumor cells and used as avaccine can induce specific tumor immunity, presumably through thetransport of tumor-specific peptides to antigen-presenting cells (APCs)(J Immunol 1999, 163(10):5178-5182). For example, gp96-associatedpeptides are cross-presented to CD8 cells by dendritic cells (DCs).

A vaccination system was developed for antitumor therapy by transfectinga gp96-Ig G1-Fc fusion protein into tumor cells, resulting in secretionof gp96-Ig in complex with chaperoned tumor peptides (see, J Immunother2008, 31(4):394-401, and references cited therein). Parenteraladministration of gp96-Ig secreting tumor cells triggers robust,antigen-specific CD8 cytotoxic T lymphocyte (CTL) expansion, combinedwith activation of the innate immune system. Tumor-secreted gp96 causesthe recruitment of DCs and natural killer (NK) cells to the site of gp96secretion, and mediates DC activation. Further, the endocytic uptake ofgp96 and its chaperoned peptides triggers peptide cross presentation viamajor MHC class I, as well as strong, cognate CD8 activation independentof CD4 cells.

The vectors provided herein contain a nucleotide sequence that encodes agp96-Ig fusion protein. The coding region of human gp96 is 2,412 basesin length (SEQ ID NO:1), and encodes an 803 amino acid protein (SEQ IDNO:2) that includes a 21 amino acid signal peptide at the aminoterminus, a potential transmembrane region rich in hydrophobic residues,and an ER retention peptide sequence at the carboxyl terminus (GENBANK®Accession No. X15187; see, Maki et al., Proc Natl Acad Sci USA 1990,87:5658-5562). The DNA and protein sequences of human gp96 follow:

atgagggccctgtgggtgctgggcctctgctgcgtcctgctgaccttcgggtcggtcagagctgacgatgaagttgatgtggtacagtagaagaggatctgggtaaaagtagagaaggatcaaggacggatgatgaagtagtacagagagaggaagaagctattcagttggatggattaaatgcatcacaaataagagaacttagagagaagtcggaaaagtttgccttccaagccgaagttaacagaatgatgaaacttatcatcaattcattgtataaaaataaagagattttcctgagagaactgatttcaaatgcttctgatgctttagataagataaggctaatatcactgactgatgaaaatgctctttctggaaatgaggaactaacagtcaaaattaagtgtgataaggagaagaacctgctgcatgtcacagacaccggtgtaggaatgaccagagaagagttggttaaaaaccttggtaccatagccaaatctgggacaagcgagtttttaaacaaaatgactgaagcacaggaagatggccagtcaacttctgaattgattggccagtttggtgtcggtttctattccgccttccttgtagcagataaggttattgtcacttcaaaacacaacaacgatacccagcacatctgggagtctgactccaatgaattttctgtaattgctgacccaagaggaaacactctaggacggggaacgacaattacccttgtcttaaaagaagaagcatctgattaccttgaattggatacaattaaaaatctcgtcaaaaaatattcacagttcataaactttcctatttatgtatggagcagcaagactgaaactgttgaggagcccatggaggaagaagaagcagccaaagaagagaaagaagaatctgatgatgaagctgcagtagaggaagaagaagaagaaaagaaaccaaagactaaaaaagttgaaaaaactgtctgggactgggaacttatgaatgatatcaaaccaatatggcagagaccatcaaaagaagtagaagaagatgaatacaaagctttctacaaatcattttcaaaggaaagtgatgaccccatggcttatattcactttactgctgaaggggaagttaccttcaaatcaattttatttgtacccacatctgctccacgtggtctgtttgacgaatatggatctaaaaagagcgattacattaagctctatgtgcgccgtgtattcatcacagacgacttccatgatatgatgcctaaatacctcaattttgtcaagggtgtggtggactcagatgatctccccttgaatgtttcccgcgagactcttcagcaacataaactgcttaaggtgattaggaagaagcttgttcgtaaaacgctggacatgatcaagaagattgctgatgataaatacaatgatactttttggaaagaatttggtaccaacatcaagcttggtgtgattgaagaccactcgaatcgaacacgtcttgctaaacttcttaggttccagtcttctcatcatccaactgacattactagcctagaccagtatgtggaaagaatgaaggaaaaacaagacaaaatctacttcatggctgggtccagcagaaaagaggctgaatcttctccatttgttgagcgacttctgaaaaagggctatgaagttatttacctcacagaacctgtggatgaatactgtattcaggcccttcccgaatttgatgggaagaggttccagaatgttgccaaggaaggagtgaagttcgatgaaagtgagaaaactaaggagagtcgtgaagcagttgagaaagaatttgagcctctgctgaattggatgaaagataaagcccttaaggacaagattgaaaaggctgtggtgtctcagcgcctgacagaatctccgtgtgctttggtggccagccagtacggatggtctggcaacatggagagaatcatgaaagcacaagcgtaccaaacgggcaaggacatctctacaaattactatgcgagtcagaagaaaacatttgaaattaatcccagacacccgctgatcagagacatgcttcgacgaattaaggaagatgaagatgataaaacagttttggatcttgctgtggttttgtttgaaacagcaacgcttcggtcagggtatcttttaccagacactaaagcatatggagatagaatagaaagaatgcttcgcctcagtttgaacattgaccctgatgcaaaggtggaagaagagcccgaagaagaacctgaagagacagcagaagacacaacagaagacacagagcaagacgaagatgaagaaatggatgtgggaacagatgaagaagaagaaacagcaaaggaatctacagctgaaaaagatgaattgtaa (SEQ ID NO: 1)

MRALWVLGLCCVLLTFGSVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDGLNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISLTDENALSGNEELTVKIKCDKEKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTEAQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNTLGRGTTITLVLKEEASDYLELDTIKNLVKKYSQFINFPIYVWSSKTETVEEPMEEEEAAKEEKEESDDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEEDEYKAFYKSFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITDDFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADDKYNDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHPTDITSLDQYVERMKEKQDKIYFMAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDESEKTKESREAVEKEFEPLLNWMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMERIMKAQAYQTGKDISTNYYASQKKTFEINPRHPLIRDMLRRIKEDEDDKTVLDLAVVLFETATLRSGYLLPDTKAYGDRIERMLRLSLNIDPDAKVEEEPEEEPEETAEDTTEDTEQDEDEEMDVGTDEEEETAKESTAEK DEL(SEQ ID NO:2).

A nucleic acid encoding a gp96-Ig fusion sequence can be produced usingthe methods described in U.S. Pat. No. 8,685,384, which is incorporatedherein by reference in its entirety. In some embodiments, the gp96portion of a gp96-Ig fusion protein can contain all or a portion of awild type gp96 sequence (e.g., the human sequence set forth in SEQ IDNO:2). For example, a secretable gp96-Ig fusion protein can include thefirst 799 amino acids of SEQ ID NO:2, such that it lacks the C-terminalKDEL (SEQ ID NO:3) sequence. Alternatively, the gp96 portion of thefusion protein can have an amino acid sequence that contains one or moresubstitutions, deletions, or additions as compared to the first 799amino acids of the wild type gp96 sequence, such that it has at least90% (e.g., at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, or atleast 99%) sequence identity to the wild type polypeptide.

As used throughout this disclosure, the percent sequence identitybetween a particular nucleic acid or amino acid sequence and a sequencereferenced by a particular sequence identification number is determinedas follows. First, a nucleic acid or amino acid sequence is compared tothe sequence set forth in a particular sequence identification numberusing the BLAST 2 Sequences (Bl2seq) program from the stand-aloneversion of BLASTZ containing BLASTN version 2.0.14 and BLASTP version2.0.14. This stand-alone version of BLASTZ can be obtained online atfr.com/blast or at ncbi.nlm.nih.gov. Instructions explaining how to usethe Bl2seq program can be found in the readme file accompanying BLASTZ.Bl2seq performs a comparison between two sequences using either theBLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acidsequences, while BLASTP is used to compare amino acid sequences. Tocompare two nucleic acid sequences, the options are set as follows: -iis set to a file containing the first nucleic acid sequence to becompared (e.g., C:\seq1.txt); -j is set to a file containing the secondnucleic acid sequence to be compared (e.g., C:\seq2.txt); -p is set toblastn; -o is set to any desired file name (e.g., C:\output.txt); -q isset to -1; -r is set to 2; and all other options are left at theirdefault setting. For example, the following command can be used togenerate an output file containing a comparison between two sequences:C:\Bl2seq -i c:\seq1.txt -j c:\seq2.txt -p blastn -o c:\output.txt -q -1-r 2. To compare two amino acid sequences, the options of Bl2seq are setas follows: -i is set to a file containing the first amino acid sequenceto be compared (e.g., C:\seq1.txt); -j is set to a file containing thesecond amino acid sequence to be compared (e.g., C:\seq2.txt); -p is setto blastp; -o is set to any desired file name (e.g., C:\output.txt); andall other options are left at their default setting. For example, thefollowing command can be used to generate an output file containing acomparison between two amino acid sequences: C:\Bl2seq -i c:\seq1.txt -jc:\seq2.txt -p blastp -o c:\output.txt. If the two compared sequencesshare homology, then the designated output file will present thoseregions of homology as aligned sequences. If the two compared sequencesdo not share homology, then the designated output file will not presentaligned sequences.

Once aligned, the number of matches is determined by counting the numberof positions where an identical nucleotide or amino acid residue ispresented in both sequences. The percent sequence identity is determinedby dividing the number of matches either by the length of the sequenceset forth in the identified sequence (e.g., SEQ ID NO:1), or by anarticulated length (e.g., 100 consecutive nucleotides or amino acidresidues from a sequence set forth in an identified sequence), followedby multiplying the resulting value by 100. For example, a nucleic acidsequence that has 2,200 matches when aligned with the sequence set forthin SEQ ID NO:1 is 91.2 percent identical to the sequence set forth inSEQ ID NO:1 (i.e., 2,000 ÷ 2,412 × 100 = 91.2). It is noted that thepercent sequence identity value is rounded to the nearest tenth. Forexample, 75.11, 75.12, 75.13, and 75.14 is rounded down to 75.1, while75.15, 75.16, 75.17, 75.18, and 75.19 is rounded up to 75.2. It also isnoted that the length value will always be an integer.

Thus, in some embodiments, the gp96 portion of nucleic acid encoding agp96-Ig fusion polypeptide can encode an amino acid sequence thatdiffers from the wild type gp96 polypeptide at one or more amino acidpositions, such that it contains one or more conservative substitutions,non-conservative substitutions, splice variants, isoforms, homologuesfrom other species, and polymorphisms.

As defined herein, a “conservative substitution” denotes the replacementof an amino acid residue by another, biologically similar, residue.Typically, biological similarity, as referred to above, reflectssubstitutions on the wild type sequence with conserved amino acids. Forexample, conservative amino acid substitutions would be expected to havelittle or no effect on biological activity, particularly if theyrepresent less than 10% of the total number of residues in thepolypeptide or protein. Conservative substitutions may be made, forinstance, on the basis of similarity in polarity, charge, size,solubility, hydrophobicity, hydrophilicity, and/or the amphipathicnature of the amino acid residues involved. The 20 naturally occurringamino acids can be grouped into the following six standard amino acidgroups: (1) hydrophobic: Met, Ala, Val, Leu, lle; (2) neutralhydrophilic: Cys, Ser, Thr; Asn, Gln; (3) acidic: Asp, Glu; (4) basic:His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro;and (6) aromatic: Trp, Tyr, Phe. Accordingly, conservative substitutionsmay be effected by exchanging an amino acid by another amino acid listedwithin the same group of the six standard amino acid groups shown above.For example, the exchange of Asp by Glu retains one negative charge inthe so modified polypeptide. In addition, glycine and proline may besubstituted for one another based on their ability to disrupt α-helices.Additional examples of conserved amino acid substitutions, include,without limitation, the substitution of one hydrophobic residue foranother, such as isoleucine, valine, leucine, or methionine, or thesubstitution of one polar residue for another, such as the substitutionof arginine for lysine, glutamic for aspartic acid, or glutamine forasparagine, and the like. The term “conservative substitution” alsoincludes the use of a substituted amino acid residue in place of anun-substituted parent amino acid residue, provided that antibodiesraised to the substituted polypeptide also immunoreact with theun-substituted polypeptide.

As used herein, “non-conservative substitutions” are defined asexchanges of an amino acid by another amino acid listed in a differentgroup of the six standard amino acid groups (1) to (6) shown above.

In various embodiments, the substitutions may also include non-classicalamino acids (e.g., selenocysteine, pyrrolysine, N-formylmethionineβ-alanine, GABA and δ-Aminolevulinic acid, 4-aminobenzoic acid (PABA),D-isomers of the common amino acids, 2,4-diaminobutyric acid, α-aminoisobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ-Abu,ε-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline,sarcosme, citrulline, homocitrulline, cysteic acid, t-butylglycine,t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine,fluoro-amino acids, designer amino acids such as β methyl amino acids, Cα-methyl amino acids, N α-methyl amino acids, and amino acid analogs ingeneral).

Mutations may also be made to the nucleotide sequences of the presentfusion proteins by reference to the genetic code, including taking intoaccount codon degeneracy.

The Ig portion (“tag”) of a gp96-Ig fusion protein can contain, forexample, a non-variable portion of an immunoglobulin molecule (e.g., anIgG1, IgG2, IgG3, IgG4, IgM, IgA, or IgE molecule). Typically, suchportions contain at least functional CH2 and CH3 domains of the constantregion of an immunoglobulin heavy chain. Fusions also can be made usingthe carboxyl terminus of the Fc portion of a constant domain, or aregion immediately amino-terminal to the CH1 of the heavy or lightchain. The Ig tag can be from a mammalian (e.g., human, mouse, monkey,or rat) immunoglobulin, but human immunoglobulin can be particularlyuseful when the gp96-Ig fusion is intended for in vivo use for humans.

DNAs encoding immunoglobulin light or heavy chain constant regions areknown or readily available from cDNA libraries. See, for example, Adamset al., Biochemistry 1980, 19:2711-2719; Gough et al., Biochemistry 198019:2702-2710; Dolby et al., Proc Natl Acad Sci USA 1980, 77:6027-6031;Rice et al., Proc Natl Acad Sci USA 1982, 79:7862-7865; Falkner et al.,Nature 1982, 298:286-288; and Morrison et al., Ann Rev Immunol 1984,2:239-256. Since many immunological reagents and labeling systems areavailable for the detection of immunoglobulins, gp96-Ig fusion proteinscan readily be detected and quantified by a variety of immunologicaltechniques known in the art, such as enzyme-linked immunosorbent assay(ELISA), immunoprecipitation, and fluorescence activated cell sorting(FACS). Similarly, if the peptide tag is an epitope with readilyavailable antibodies, such reagents can be used with the techniquesmentioned above to detect, quantitate, and isolate gp96-Ig fusions.

In various embodiments, the gp96-Ig fusion protein and/or thecostimulatory molecule fusions, comprises a linker. In variousembodiments, the linker may be derived from naturally-occurringmulti-domain proteins or are empirical linkers as described, forexample, in Chichili et al., (2013), Protein Sci. 22(2):153-167, Chen etal., (2013), Adv Drug Deliv Rev. 65(10):1357-1369, the entire contentsof which are hereby incorporated by reference. In some embodiments, thelinker may be designed using linker designing databases and computerprograms such as those described in Chen et al., (2013), Adv Drug DelivRev. 65(10):1357-1369 and Crasto et. al., (2000), Protein Eng.13(5):309-312, the entire contents of which are hereby incorporated byreference.

In some embodiments, the linker is a synthetic linker such as PEG.

In other embodiments, the linker is a polypeptide. In some embodiments,the linker is less than about 100 amino acids long. For example, thelinker may be less than about 100, about 95, about 90, about 85, about80, about 75, about 70, about 65, about 60, about 55, about 50, about45, about 40, about 35, about 30, about 25, about 20, about 19, about18, about 17, about 16, about 15, about 14, about 13, about 12, about11, about 10, about 9, about 8, about 7, about 6, about 5, about 4,about 3, or about 2 amino acids long. In some embodiments, the linker isflexible. In another embodiment, the linker is rigid. In variousembodiments, the linker is substantially comprised of glycine and serineresidues (e.g., about 30%, or about 40%, or about 50%, or about 60%, orabout 70%, or about 80%, or about 90%, or about 95%, or about 97%glycines and serines).

In various embodiments, the linker is a hinge region of an antibody(e.g., of IgG, IgA, IgD, and IgE, inclusive of subclasses (e.g. IgG1,IgG2, IgG3, and IgG4, and IgA1 and IgA2)). The hinge region, found inIgG, IgA, IgD, and IgE class antibodies, acts as a flexible spacer,allowing the Fab portion to move freely in space. In contrast to theconstant regions, the hinge domains are structurally diverse, varying inboth sequence and length among immunoglobulin classes and subclasses.For example, the length and flexibility of the hinge region varies amongthe IgG subclasses. The hinge region of IgG1 encompasses amino acids216-231 and, because it is freely flexible, the Fab fragments can rotateabout their axes of symmetry and move within a sphere centered at thefirst of two inter-heavy chain disulfide bridges. IgG2 has a shorterhinge than IgG1, with 12 amino acid residues and four disulfide bridges.The hinge region of IgG2 lacks a glycine residue, is relatively short,and contains a rigid poly-proline double helix, stabilized by extrainter-heavy chain disulfide bridges. These properties restrict theflexibility of the IgG2 molecule. IgG3 differs from the other subclassesby its unique extended hinge region (about four times as long as theIgG1 hinge), containing 62 amino acids (including 21 prolines and 11cysteines), forming an inflexible poly-proline double helix. In IgG3,the Fab fragments are relatively far away from the Fc fragment, givingthe molecule a greater flexibility. The elongated hinge in IgG3 is alsoresponsible for its higher molecular weight compared to the othersubclasses. The hinge region of IgG4 is shorter than that of IgG1 andits flexibility is intermediate between that of IgG1 and IgG2. Theflexibility of the hinge regions reportedly decreases in the orderIgG3>IgG1>IgG4>IgG2.

Additional illustrative linkers include, but are not limited to, linkershaving the sequence LE, GGGGS (SEQ ID NO:26), (GGGGS)_(n) (n=1-4) (SEQID NO: 27), (Gly)₈ (SEQ ID NO:28), (Gly)₆ (SEQ ID NO:29), (EAAAK)_(n)(n=1-3) (SEQ ID NO: 30), A(EAAAK)_(n)A (n = 2-5) (SEQ ID NO: 31),AEAAAKEAAAKA (SEQ ID NO: 32), A(EAAAK)₄ALEA(EAAAK)₄A (SEQ ID NO: 33),PAPAP (SEQ ID NO: 34), KESGSVSSEQLAQFRSLD (SEQ ID NO: 35),EGKSSGSGSESKST(SEQ ID NO: 36), GSAGSAAGSGEF (SEQ ID NO: 37), and(XP)_(n), with X designating any amino acid, e.g., Ala, Lys, or Glu.

In various embodiments, the linker may be functional. For example,without limitation, the linker may function to improve the foldingand/or stability, improve the expression, improve the pharmacokinetics,and/or improve the bioactivity of the present compositions. In anotherexample, the linker may function to target the compositions to aparticular cell type or location.

In some embodiments, a gp96 peptide can be fused to the hinge, CH2 andCH3 domains of murine IgG1 (Bowen et al., J Immunol 1996, 156:442-449).This region of the IgG1 molecule contains three cysteine residues thatnormally are involved in disulfide bonding with other cysteines in theIg molecule. Since none of the cysteines are required for the peptide tofunction as a tag, one or more of these cysteine residues can besubstituted by another amino acid residue, such as, for example, serine.

Various leader sequences known in the art also can be used for efficientsecretion of gp96-Ig fusion proteins from bacterial and mammalian cells(see, von Heijne, J Mol Biol 1985, 184:99-105). Leader peptides can beselected based on the intended host cell, and may include bacterial,yeast, viral, animal, and mammalian sequences. For example, the herpesvirus glycoprotein D leader peptide is suitable for use in a variety ofmammalian cells. Another leader peptide for use in mammalian cells canbe obtained from the V-J2-C region of the mouse immunoglobulin kappachain (Bernard et al., Proc Natl Acad Sci USA 1981, 78:5812-5816). DNAsequences encoding peptide tags or leader peptides are known or readilyavailable from libraries or commercial suppliers, and are suitable inthe fusion proteins described herein.

Furthermore, in various embodiments, one may substitute the gp96 of thepresent disclosure with one or more vaccine proteins. For instance,various heat shock proteins are among the vaccine proteins. In variousembodiments, the heat shock protein is one or more of a small hsp,hsp40, hsp60, hsp70, hsp90, and hsp110 family member, inclusive offragments, variants, mutants, derivatives or combinations thereof(Hickey, et al., 1989, Mol. Cell. Biol. 9:2615-2626; Jindal, 1989, Mol.Cell. Biol. 9:2279-2283).

T-Cell Co-Stimulation

In addition to a gp96-Ig fusion protein, the expression vectors providedherein can encode one or more biological response modifiers. In variousembodiments, the present expression vectors can encode one or more Tcell costimultory molecules.

In various embodiments, the present expression vectors allow for arobust, antigen-specific CD8 cytotoxic T lymphocyte (CTL) expansion. Invarious embodiments, the present expression vectors selectively enhanceCD8 cytotoxic T lymphocyte (CTL) and do not substantially enhance T celltypes that can be pro-tumor, and which include, but are not limited to,Tregs, CD4+ and/or CD8+ T cells expressing one or more checkpointinhibitory receptors, Th2 cells and Th17 cells. Checkpoint inhibitoryreceptors refers to receptors (e.g., CTLA-4, B7-H3, B7-H4, TIM-3)expressed on immune cells that prevent or inhibit uncontrolled immuneresponses. For instance, the present expression vectors do notsubstantially enhance FOXP3⁺ regulatory T cells. In some embodiments,this selective CD8 T cell enhancement is in contrast to the non-specificT cell enhancement observed with a combination therapy of a gp-96 fusionand an antibody against a T cell costimultory molecule.

For example, a vector can encode an agonist of OX40 (e.g., an OX40ligand-lg (OX40L-lg) fusion, or a fragment thereof that binds OX40), anagonist of inducible T-cell costimulator (ICOS) (e.g., an ICOS ligand-lg(ICOSL-Ig) fusion, or a fragment thereof that binds ICOS), an agonist ofCD40 (e.g., a CD40L-lg fusion protein, or fragment thereof), an agonistof CD27 (e.g., a CD70-lg fusion protein or fragment thereof), or anagonist of 4-1BB (e.g., a 4-1BB ligand-Ig (4-1BBL-Ig) fusion, or afragment thereof that binds 4-1BB). In some embodiments, a vector canencode an agonist of TNFRSF25 (e.g., a TL1A-lg fusion, or a fragmentthereof that binds TNFRSF25), or an agonist of glucocorticoid-inducedtumor necrosis factor receptor (GITR) (e.g., a GITR ligand-lg (GITRL-Ig)fusion, or a fragment thereof that binds GITR), or an agonist of CD40(e.g., a CD40 ligand-Ig (CD40L-lg) fusion, or a fragment thereof thatbinds CD40); or an agonist of CD27 (e.g., a CD27 ligand-lg (e.g.,CD70L-lg) fusion, or a fragment thereof that binds CD40).

ICOS is an inducible T cell costimulatory receptor molecule thatdisplays some homology to CD28 and CTLA-4, and interacts with B7-H2expressed on the surface of antigen-presenting cells. ICOS has beenimplicated in the regulation of cell-mediated and humoral immuneresponses.

4-1BB is a type 2 transmembrane glycoprotein belonging to the TNFsuperfamily, and is expressed on activated T Lymphocytes.

OX40 (also referred to as CD134 or TNFRSF4) is a T cell costimulatorymolecule that is engaged by OX40L, and frequently is induced in antigenpresenting cells and other cell types. OX40 is known to enhance cytokineexpression and survival of effector T cells.

GITR (TNFRSF18) is a T cell costimulatory molecule that is engaged byGITRL and is preferentially expressed in FoxP3+ regulatory T cells. GITRplays a significant role in the maintenance and function of Treg withinthe tumor microenvironment.

TNFRSF25 is a T cell costimulatory molecule that is preferentiallyexpressed in CD4+ and CD8+ T cells following antigen stimulation.Signaling through TNFRSF25 is provided by TL1A, and functions to enhanceT cell sensitivity to IL-2 receptor mediated proliferation in a cognateantigen dependent manner.

CD40 is a costimulatory protein found on various antigen presentingcells which plays a role in their activation. The binding of CD40L(CD154) on T_(H) cells to CD40 activates antigen presenting cells andinduces a variety of downstream effects.

CD27 a T cell costimulatory molecule belonging to the TNF superfamilywhich plays a role in the generation and long-term maintenance of T cellimmunity. It binds to a ligand CD70 in various immunological processes.

Additional costimulatory molecules that may be utilized in the presentinvention include, but are not limited to, HVEM, CD28, CD30, CD30L,CD40, CD70, LIGHT(CD258), B7-1, and B7-2.

As for the gp96-Ig fusions, the Ig portion (“tag”) of the T cellcostimulatory fusion protein can contain, a non-variable portion of animmunoglobulin molecule (e.g., an IgG1, IgG2, IgG3, IgG4, IgM, IgA, orIgE molecule). As described above, such portions typically contain atleast functional CH2 and CH3 domains of the constant region of animmunoglobulin heavy chain. In some embodiments, a T cell costimulatorypeptide can be fused to the hinge, CH2 and CH3 domains of murine IgG1(Bowen et al., J Immunol 1996, 156:442-449). The Ig tag can be from amammalian (e.g., human, mouse, monkey, or rat) immunoglobulin, but humanimmunoglobulin can be particularly useful when the fusion protein isintended for in vivo use for humans. Again, DNAs encoding immunoglobulinlight or heavy chain constant regions are known or readily availablefrom cDNA libraries. Various leader sequences as described above alsocan be used for secretion of T cell costimulatory fusion proteins frombacterial and mammalian cells.

A representative nucleotide optimized sequence (SEQ ID NO:4) encodingthe extracellular domain of human ICOSL fused to lg, and the amino acidsequence of the encoded fusion (SEQ ID NO:5) are provided:

ATGAGACTGGGAAGCCCTGGCCTGCTGTTTCTGCTGTTCAGCAGCCTGAGAGCCGACACCCAGGAAAAAGAAGTGCGGGCCATGGTGGGAAGCGACGTGGAACTGAGCTGCGCCTGTCCTGAGGGCAGCAGATTCGACCTGAACGACGTGTACGTGTACTGGCAGACCAGCGAGAGCAAGACCGTCGTGACCTACCACATCCCCCAGAACAGCTCCCTGGAAAACGTGGACAGCCGGTACAGAAACCGGGCCCTGATGTCTCCTGCCGGCATGCTGAGAGGCGACTTCAGCCTGCGGCTGTTCAACGTGACCCCCCAGGACGAGCAGAAATTCCACTGCCTGGTGCTGAGCCAGAGCCTGGGCTTCCAGGAAGTGCTGAGCGTGGAAGTGACCCTGCACGTGGCCGCCAATTTCAGCGTGCCAGTGGTGTCTGCCCCCCACAGCCCTTCTCAGGATGAGCTGACCTTCACCTGTACCAGCATCAACGGCTACCCCAGACCCAATGTGTACTGGATCAACAAGACCGACAACAGCCTGCTGGACCAGGCCCTGCAGAACGATACCGTGTTCCTGAACATGCGGGGCCTGTACGACGTGGTGTCCGTGCTGAGAATCGCCAGAACCCCCAGCGTGAACATCGGCTGCTGCATCGAGAACGTGCTGCTGCAGCAGAACCTGACCGTGGGCAGCCAGACCGGCAACGACATCGGCGAGAGAGACAAGATCACCGAGAACCCCGTGTCCACCGGCGAGAAGAATGCCGCCACCTCTAAGTACGGCCCTCCCTGCCCTTCTTGCCCAGCCCCTGAATTTCTGGGCGGACCCTCCGTGTTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGGGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCTGTGCTGACCGTGCTGCACCAGGATTGGCTGAGCGGCAAAGAGTACAAGTGCAAGGTGTCCAGCAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGCAACGCCACCGGCCAGCCCAGGGAACCCCAGGTGTACACACTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAGGGCTTCTACCCCTCCGATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCAGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCTCATTCTTCCTGTACTCCCGGCTGACAGTGGACAAGAGCAGCTGGCAGGAAGGCAACGTGTTCAGCTGCAGCGTGATGCACGAAGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGCA AATGA (SEQ ID NO:4)

MRLGSPGLLFLLFSSLRADTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPNVYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAATSKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLSGKEYKCKVSSKGLPSSIEKTISNATGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSSWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:5).

A representative nucleotide optimized sequence (SEQ ID NO:6) encodingthe extracellular domain of human 4-1BBL fused to Ig, and the encodedamino acid sequence (SEQ ID NO:7) are provided:

ATGTCTAAGTACGGCCCTCCCTGCCCTAGCTGCCCTGCCCCTGAATTTCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAGCGGCAAAGAGTACAAGTGCAAGGTGTCCAGCAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAACGCCACCGGCCAGCCCAGGGAACCCCAGGTGTACACACTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAGGGCTTCTACCCCTCCGATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAGCAGACTGACCGTGGACAAGAGCAGCTGGCAGGAAGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGAGCCTGGGCAAGGCCTGTCCATGGGCTGTGTCTGGCGCTAGAGCCTCTCCTGGATCTGCCGCCAGCCCCAGACTGAGAGAGGGACCTGAGCTGAGCCCCGATGATCCTGCCGGACTGCTGGATCTGAGACAGGGCATGTTCGCCCAGCTGGTGGCCCAGAACGTGCTGCTGATCGATGGCCCCCTGAGCTGGTACAGCGATCCTGGACTGGCTGGCGTGTCACTGACAGGCGGCCTGAGCTACAAAGAGGACACCAAAGAACTGGTGGTGGCCAAGGCCGGCGTGTACTACGTGTTCTTTCAGCTGGAACTGCGGAGAGTGGTGGCCGGCGAAGGATCCGGCTCTGTGTCTCTGGCTCTGCATCTGCAGCCCCTGAGATCTGCTGCTGGCGCTGCTGCTCTGGCCCTGACAGTGGACCTGCCTCCTGCCTCTAGCGAGGCCAGAAACAGCGCATTCGGGTTTCAAGGCAGACTGCTGCACCTGTCTGCCGGCCAGAGACTGGGAGTGCATCTGCACACAGAGGCCAGAGCCAGGCACGCCTGGCAGCTGACTCAGGGCGCTACAGTGCTGGGCCTGTTCAGAGTGACCCCCGAGATTCCAGCCGGCCTGCCTAGCCCCAGATCCG AATGA (SEQ ID NO:6)

MSKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLSGKEYKCKVSSKGLPSSIEKTISNATGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSSWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKACPWAVSGARASPGSAASPRLREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE (SEQ ID NO:7).

A representative nucleotide optimized sequence (SEQ ID NO:8) encodingthe extracellular domain of human TL1A fused to Ig, and the encodedamino acid sequence (SEQ ID NO:9) are provided:

ATGTCTAAGTACGGCCCTCCCTGCCCTAGCTGCCCTGCCCCTGAATTTCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAGCGGCAAAGAGTACAAGTGCAAGGTGTCCAGCAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAACGCCACCGGCCAGCCCAGGGAACCCCAGGTGTACACACTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAGGGCTTCTACCCCTCCGATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAGCAGACTGACCGTGGACAAGAGCAGCTGGCAGGAAGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGAGCCTGGGCAAGATCGAGGGCCGGATGGATAGAGCCCAGGGCGAAGCCTGCGTGCAGTTCCAGGCTCTGAAGGGCCAGGAATTCGCCCCCAGCCACCAGCAGGTGTACGCCCCTCTGAGAGCCGACGGCGATAAGCCTAGAGCCCACCTGACAGTCGTGCGGCAGACCCCTACCCAGCACTTCAAGAATCAGTTCCCCGCCCTGCACTGGGAGCACGAACTGGGCCTGGCCTTCACCAAGAACAGAATGAACTACACCAACAAGTTTCTGCTGATCCCCGAGAGCGGCGACTACTTCATCTACAGCCAAGTGACCTTCCGGGGCATGACCAGCGAGTGCAGCGAGATCAGACAGGCCGGCAGACCTAACAAGCCCGACAGCATCACCGTCGTGATCACCAAAGTGACCGACAGCTACCCCGAGCCCACCCAGCTGCTGATGGGCACCAAGAGCGTGTGCGAAGTGGGCAGCAACTGGTTCCAGCCCATCTACCTGGGCGCCATGTTTAGTCTGCAAGAGGGCGACAAGCTGATGGTCAACGTGTCCGACATCAGCCTGGTGGATTACACCAAAGAGGACAAGACCTTCTTCGGCGCCTTTCTGCTCTGA (SEQ ID NO:8).

MSKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRWSVLTVLHQDWLSGKEYKCKVSSKGLPSSIEKTISNATGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSSWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKIEGRMDRAQGEACVQFQALKGQEFAPSHQQVYAPLRADGDKPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECSEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAFLL (SEQ ID NO:9).

A representative nucleotide optimized sequence (SEQ ID NO:10) encodinghuman OX40L-Ig, and the encoded amino acid sequence (SEQ ID NO:11) areprovided:

ATGTCTAAGTACGGCCCTCCCTGCCCTAGCTGCCCTGCCCCTGAATTTCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAGCGGCAAAGAGTACAAGTGCAAGGTGTCCAGCAAGGGCCTGCCCAGCAGCATCGAGAAAACCATCAGCAACGCCACCGGCCAGCCCAGGGAACCCCAGGTGTACACACTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAGGGCTTCTACCCCTCCGATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAGCAGACTGACCGTGGACAAGAGCAGCTGGCAGGAAGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGAGCCTGGGCAAGATCGAGGGCCGGATGGATCAGGTGTCACACAGATACCCCCGGATCCAGAGCATCAAAGTGCAGTTTACCGAGTACAAGAAAGAGAAGGGCTTTATCCTGACCAGCCAGAAAGAGGACGAGATCATGAAGGTGCAGAACAACAGCGTGATCATCAACTGCGACGGGTTCTACCTGATCAGCCTGAAGGGCTACTTCAGTCAGGAAGTGAACATCAGCCTGCACTACCAGAAGGACGAGGAACCCCTGTTCCAGCTGAAGAAAGTGCGGAGCGTGAACAGCCTGATGGTGGCCTCTCTGACCTACAAGGACAAGGTGTACCTGAACGTGACCACCGACAACACCAGCCTGGACGACTTCCACGTGAACGGCGGCGAGCTGATCCTGATTCACCAGAACCCCGGCGAGTTCTGCGTGCTCTGA (SEQ ID NO:10).

MSKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRWSVLTVLHQDWLSGKEYKCKVSSKGLPSSIEKTISNATGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSSWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKIEGRMDQVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNSVIINCDGFYLISLKGYFSQEVNISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDKVYLNVTTDNTSLDDFHVNGGELILIHQNPGEFCVL (SEQ ID NO:11).

Representative nucleotide and amino acid sequences for human TL1A areset forth in SEQ ID NO:12 and SEQ ID NO:13, respectively:

TCCCAAGTAGCTGGGACTACAGGAGCCCACCACCACCCCCGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCAAGATGGTCTTGATCACCTGACCTCGTGATCCACCCGCCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGCGCCCGGCCTCCATTCAAGTCTTTATTGAATATCTGCTATGTTCTACACACTGTTCTAGGTGCTGGGGATGCAACAGGGGACAAAATAGGCAAAATCCCTGTCCTTTTGGGGTTGACATTCTAGTGACTCTTCATGTAGTCTAGAAGAAGCTCAGTGAATAGTGTCTGTGGTTGTTACCAGGGACACAATGACAGGAACATTCTTGGGTAGAGTGAGAGGCCTGGGGAGGGAAGGGTCTCTAGGATGGAGCAGATGCTGGGCAGTCTTAGGGAGCCCCTCCTGGCATGCACCCCCTCATCCCTCAGGCCACCCCCGTCCCTTGCAGGAGCACCCTGGGGAGCTGTCCAGAGCGCTGTGCCGCTGTCTGTGGCTGGAGGCAGAGTAGGTGGTGTGCTGGGAATGCGAGTGGGAGAACTGGGATGGACCGAGGGGAGGCGGGTGAGGAGGGGGGCAACCACCCAACACCCACCAGCTGCTTTCAGTGTTCTGGGTCCAGGTGCTCCTGGCTGGCCTTGTGGTCCCCCTCCTGCTTGGGGCCACCCTGACCTACACATACCGCCACTGCTGGCCTCACAAGCCCCTGGTTACTGCAGATGAAGCTGGGATGGAGGCTCTGACCCCACCACCGGCCACCCATCTGTCACCCTTGGACAGCGCCCACACCCTTCTAGCACCTCCTGACAGCAGTGAGAAGATCTGCACCGTCCAGTTGGTGGGTAACAGCTGGACCCCTGGCTACCCCGAGACCCAGGAGGCGCTCTGCCCGCAGGTGACATGGTCCTGGGACCAGTTGCCCAGCAGAGCTCTTGGCCCCGCTGCTGCGCCCACACTCTCGCCAGAGTCCCCAGCCGGCTCGCCAGCCATGATGCTGCAGCCGGGCCCGCAGCTCTACGACGTGATGGACGCGGTCCCAGCGCGGCGCTGGAAGGAGTTCGTGCGCACGCTGGGGCTGCGCGAGGCAGAGATCGAAGCCGTGGAGGTGGAGATCGGCCGCTTCCGAGACCAGCAGTACGAGATGCTCAAGCGCTGGCGCCAGCAGCAGCCCGCGGGCCTCGGAGCCGTTTACGCGGCCCTGGAGCGCATGGGGCTGGACGGCTGCGTGGAAGACTTGCGCAGCCGCCTGCAGCGCGGCCCGTGACACGGCGCCCACTTGCCACCTAGGCGCTCTGGTGGCCCTTGCAGAAGCCCTAAGTACGGTTACTTATGCGTGTAGACATTTTATGTCACTTATTAAGCCGCTGGCACGGCCCTGCGTAGCAGCACCAGCCGGCCCCACCCCTGCTCGCCCCTATCGCTCCAGCCAAGGCGAAGAAGCACGAACGAATGTCGAGAGGGGGTGAAGACATTTCTCAACTTCTCGGCCGGAGTTTGGCTGAGATCGCGGTATTAAATCTGTGAAAGAAAACAAAACAAAACAA (SEQ ID NO: 12).

MEQRPRGCAAVAAALLLVLLGARAQGGTRSPRCDCAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCPQDTFLAWENHHNSECARCQACDEQASQVALENCSAVADTRCGCKPGWFVECQVSQCVSSSPFYCQPCLDCGALHRHTRLLCSRRDTDCGTCLPGFYEHGDGCVSCPTPPPSLAGAPWGAVQSAVPLSVAGGRVGVFWVQVLLAGLVVPLLLGATLTYTYRHCWPHKPLVTADEAGMEALTPPPATHLSPLDSAHTLLAPPDSSEKICTVQLVGNSWTPGYPETQEALCPQVTWSWDQLPSRALGPAAAPTLSPESPAGSPAMMLQPGPQLYDVMDAVPARRWKEFVRTLGLREAEIEAVEVEIGRFRDQQYEMLKRWRQQQPAGLGAVYAALERMGLDGCVEDLRSRLQRGP (SEQ ID NO:13).

Representative nucleotide and amino acid sequences for human HVEM areset forth in SEQ ID NO:38 (accession no. CR456909) and SEQ ID NO:39,respectively (accession no. CR456909):

ATGGAGCCTCCTGGAGACTGGGGGCCTCCTCCCTGGAGATCCACCCCCAAAACCGACGTCTTGAGGCTGGTGCTGTATCTCACCTTCCTGGGAGCCCCCTGCTACGCCCCAGCTCTGCCGTCCTGCAAGGAGGACGAGTACCCAGTGGGCTCCGAGTGCTGCCCCAAGTGCAGTCCAGGTTATCGTGTGAAGGAGGCCTGCGGGGAGCTGACGGGCACAGTGTGTGAACCCTGCCCTCCAGGCACCTACATTGCCCACCTCAATGGCCTAAGCAAGTGTCTGCAGTGCCAAATGTGTGACCCAGCCATGGGCCTGCGCGCGAGCCGGAACTGCTCCAGGACAGAGAACGCCGTGTGTGGCTGCAGCCCAGGCCACTTCTGCATCGTCCAGGACGGGGACCACTGCGCCGCGTGCCGCGCTTACGCCACCTCCAGCCCGGGCCAGAGGGTGCAGAAGGGAGGCACCGAGAGTCAGGACACCCTGTGTCAGAACTGCCCCCCGGGGACCTTCTCTCCCAATGGGACCCTGGAGGAATGTCAGCACCAGACCAAGTGCAGCTGGCTGGTGACGAAGGCCGGAGCTGGGACCAGCAGCTCCCACTGGGTATGGTGGTTTCTCTCAGGGAGCCTCGTCATCGTCATTGTTTGCTCCACAGTTGGCCTAATCATATGTGTGAAAAGAAGAAAGCCAAGGGGTGATGTAGTCAAGGTGATCGTCTCCGTCCAGCGGAAAAGACAGGAGGCAGAAGGTGAGGCCACAGTCATTGAGGCCCTGCAGGCCCCTCCGGACGTCACCACGGTGGCCGTGGAGGAGACAATACCCTCATTCACGGGGAGGAGCCCAAACCATT AA(SEQ ID NO:38).

MEPPGDWGPPPWRSTPKTDVLRLVLYLTFLGAPCYAPALPSCKEDEYPVGSECCPKCSPGYRVKEACGELTGTVCEPCPPGTYIAHLNGLSKCLQCQMCDPAMGLRASRNCSRTENAVCGCSPGHFCIVQDGDHCAACRAYATSSPGQRVQKGGTESQDTLCQNCPPGTFSPNGTLEECQHQTKCSWLVTKAGAGTSSSHWVWWFLSGSLVIVIVCSTVGLIICVKRRKPRGDVVKVIVSVQRKRQEAEGEATVIEALQAPPDVTTVAVEETIPSFTGRSPNH (SEQ ID NO:39).

Representative nucleotide and amino acid sequences for human CD28 areset forth in SEQ ID NO:40 (accession no. NM_006139) and SEQ ID NO:41,respectively:

TAAAGTCATCAAAACAACGTTATATCCTGTGTGAAATGCTGCAGTCAGGATGCCTTGTGGTTTGAGTGCCTTGATCATGTGCCCTAAGGGGATGGTGGCGGTGGTGGTGGCCGTGGATGACGGAGACTCTCAGGCCTTGGCAGGTGCGTCTTTCAGTTCCCCTCACACTTCGGGTTCCTCGGGGAGGAGGGGCTGGAACCCTAGCCCATCGTCAGGACAAAGATGCTCAGGCTGCTCTTGGCTCTCAACTTATTCCCTTCAATTCAAGTAACAGGAAACAAGATTTTGGTGAAGCAGTCGCCCATGCTTGTAGCGTACGACAATGCGGTCAACCTTAGCTGCAAGTATTCCTACAATCTCTTCTCAAGGGAGTTCCGGGCATCCCTTCACAAAGGACTGGATAGTGCTGTGGAAGTCTGTGTTGTATATGGGAATTACTCCCAGCAGCTTCAGGTTTACTCAAAAACGGGGTTCAACTGTGATGGGAAATTGGGCAATGAATCAGTGACATTCTACCTCCAGAATTTGTATGTTAACCAAACAGATATTTACTTCTGCAAAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCTGACACGGACGCCTATCCAGAAGCCAGCCGGCTGGCAGCCCCCATCTGCTCAATATCACTGCTCTGGATAGGAAATGACCGCCATCTCCAGCCGGCCACCTCAGGCCCCTGTTGGGCCACCAATGCCAATTTTTCTCGAGTGACTAGACCAAATATCAAGATCATTTTGAGACTCTGAAATGAAGTAAAAGAGATTTCCTGTGACAGGCCAAGTCTTACAGTGCCATGGCCCACATTCCAACTTACCATGTACTTAGTGACTTGACTGAGAAGTTAGGGTAGAAAACAAAAAGGGAGTGGATTCTGGGAGCCTCTTCCCTTTCTCACTCACCTGCACATCTCAGTCAAGCAAAGTGTGGTATCCACAGACATTTTAGTTGCAGAAGAAAGGCTAGGAAATCATTCCTTTTGGTTAAATGGGTGTTTAATCTTTTGGTTAGTGGGTTAAACGGGGTAAGTTAGAGTAGGGGGAGGGATAGGAAGACATATTTAAAAACCATTAAAACACTGTCTCCCACTCATGAAATGAGCCACGTAGTTCCTATTTAATGCTGTTTTCCTTTAGTTTAGAAATACATAGACATTGTCTTTTATGAATTCTGATCATATTTAGTCATTTTGACCAAATGAGGGATTTGGTCAAATGAGGGATTCCCTCAAAGCAATATCAGGTAAACCAAGTTGCTTTCCTCACTCCCTGTCATGAGACTTCAGTGTTAATGTTCACAATATACTTTCGAAAGAATAAAATAGTTCTCCTACATGAAGAAAGAATATGTCAGGAAATAAGGTCACTTTATGTCAAAATTATTTGAGTACTATGGGACCTGGCGCAGTGGCTCATGCTTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACTTGAGATCAGGACCAGCCTGGTCAAGATGGTGAAACTCCGTCTGTACTAAAAATACAAAATTTAGCTTGGCCTGGTGGCAGGCACCTGTAATCCCAGCTGCCCAAGAGGCTGAGGCATGAGAATCGCTTGAACCTGGCAGGCGGAGGTTGCAGTGAGCCGAGATAGTGCCACAGCTCTCCAGCCTGGGCGACAGAGTGAGACTCCATCTCAAACAACAACAACAACAACAACAACAACAACAAACCACAAAATTATTTGAGTACTGTGAAGGATTATTTGTCTAACAGTTCATTCCAATCAGACCAGGTAGGAGCTTTCCTGTTTCATATGTTTCAGGGTTGCACAGTTGGTCTCTTTAATGTCGGTGTGGAGATCCAAAGTGGGTTGTGGAAAGAGCGTCCATAGGAGAAGTGAGAATACTGTGAAAAAGGGATGTTAGCATTCATTAGAGTATGAGGATGAGTCCCAAGAAGGTTCTTTGGAAGGAGGACGAATAGAATGGAGTAATGAAATTCTTGCCATGTGCTGAGGAGATAGCCAGCATTAGGTGACAATCTTCCAGAAGTGGTCAGGCAGAAGGTGCCCTGGTGAGAGCTCCTTTACAGGGACTTTATGTGGTTTAGGGCTCAGAGCTCCAAAACTCTGGGCTCAGCTGCTCCTGTACCTTGGAGGTCCATTCACATGGGAAAGTATTTTGGAATGTGTCTTTTGAAGAGAGCATCAGAGTTCTTAAGGGACTGGGTAAGGCCTGACCCTGAAATGACCATGGATATTTTTCTACCTACAGTTTGAGTCAACTAGAATATGCCTGGGGACCTTGAAGAATGGCCCTTCAGTGGCCCTCACCATTTGTTCATGCTTCAGTTAATTCAGGTGTTGAAGGAGCTTAGGTTTTAGAGGCACGTAGACTTGGTTCAAGTCTCGTTAGTAGTTGAATAGCCTCAGGCAAGTCACTGCCCACCTAAGATGATGGTTCTTCAACTATAAAATGGAGATAATGGTTACAAATGTCTCTTCCTATAGTATAATCTCCATAAGGGCATGGCCCAAGTCTGTCTTTGACTCTGCCTATCCCTGACATTTAGTAGCATGCCCGACATACAATGTTAGCTATTGGTATTATTGCCATATAGATAAATTATGTATAAAAATTAAACTGGGCAATAGCCTAAGAAGGGGGGAATATTGTAACACAAATTTAAACCCACTACGCAGGGATGAGGTGCTATAATATGAGGACCTTTTAACTTCCATCATTTTCCTGTTTCTTGAAATAGTTTATCTTGTAATGAAATATAAGGCACCTCCCACTTTTATGTATAGAAAGAGGTCTTTTAATTTTTTTTTAATGTGAGAAGGAAGGGAGGAGTAGGAATCTTGAGATTCCAGATCGAAAATACTGTACTTTGGTTGATTTTTAAGTGGGCTTCCATTCCATGGATTTAATCAGTCCCAAGAAGATCAAACTCAGCAGTACTTGGGTGCTGAAGAACTGTTGGATTTACCCTGGCACGTGTGCCACTTGCCAGCTTCTTGGGCACACAGAGTTCTTCAATCCAAGTTATCAGATTGTATTTGAAAATGACAGAGCTGGAGAGTTTTTTGAAATGGCAGTGGCAAATAAATAAATACTTTTTTTTAAATGGAAAGACTTGATCTATGGTAATAAATGATTTTGTTTTCTGACTGGAAAAATAGGCCTACTAAAGATGAATCACACTTGAGATGTTTCTTACTCACTCTGCACAGAAACAAAGAAGAAATGTTATACAGGGAAGTCCGTTTTCACTATTAGTATGAACCAAGAAATGGTTCAAAAACAGTGGTAGGAGCAATGCTTTCATAGTTTCAGATATGGTAGTTATGAAGAAAACAATGTCATTTGCTGCTATTATTGTAAGAGTCTTATAATTAATGGTACTCCTATAATTTTTGATTGTGAGCTCACCTATTTGGGTTAAGCATGCCAATTTAAAGAGACCAAGTGTATGTACATTATGTTCTACATATTCAGTGATAAAATTACTAAACTACTATATGTCTGCTTTAAATTTGTACTTTAATATTGTCTTTTGGTATTAAGAAAGATATGCTTTCAGAATAGATATGCTTCGCTTTGGCAAGGAATTTGGATAGAACTTGCTATTTAAAAGAGGTGTGGGGTAAATCCTTGTATAAATCTCCAGTTTAGCCTTTTTTGAAAAAGCTAGACTTTCAAATACTAATTTCACTTCAAGCAGGGTACGTTTCTGGTTTGTTTGCTTGACTTCAGTCACAATTTCTTATCAGACCAATGGCTGACCTCTTTGAGATGTCAGGCTAGGCTTACCTATGTGTTCTGTGTCATGTGAATGCTGAGAAGTTTGACAGAGATCCAACTTCAGCCTTGACCCCATCAGTCCCTCGGGTTAACTAACTGAGCCACCGGTCCTCATGGCTATTTTAATGAGGGTATTGATGGTTAAATGCATGTCTGATCCCTTATCCCAGCCATTTGCACTGCCAGCTGGGAACTATACCAGACCTGGATACTGATCCCAAAGTGTTAAATTCAACTACATGCTGGAGATTAGAGATGGTGCCAATAAAGGACCCAGAACCAGGATCTTGATTGCTATAGACTTATTAATAATCCAGGTCAAAGAGAGTGACACACACTCTCTCAAGACCTGGGGTGAGGGAGTCTGTGTTATCTGCAAGGCCATTTGAGGCTCAGAAAGTCTCTCTTTCCTATAGATATATGCATACTTTCTGACATATAGGAATGTATCAGGAATACTCAACCATCACAGGCATGTTCCTACCTCAGGGCCTTTACATGTCCTGTTTACTCTGTCTAGAATGTCCTTCTGTAGATGACCTGGCTTGCCTCGTCACCCTTCAGGTCCTTGCTCAAGTGTCATCTTCTCCCCTAGTTAAACTACCCCACACCCTGTCTGCTTTCCTTGCTTATTTTTCTCCATAGCATTTTACCATCTCTTACATTAGACATTTTTCTTATTTATTTGTAGTTTATAAGCTTCATGAGGCAAGTAACTTTGCTTTGTTTCTTGCTGTATCTCCAGTGCCCAGAGCAGTGCCTGGTATATAATAAATATTTATTGACTGAGTGAAAAAAAAAAAAAAAAA  (SEQ ID NO:40).

MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVYGNYSQQLQVYSKTGFNCDGKLGNESVTFYLQNLYVNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ IDNO:41).

Representative nucleotide and amino acid sequences for human CD30L areset forth in SEQ ID NO:42 (accession no. L09753) and SEQ ID NO:43,respectively:

CCAAGTCACATGATTCAGGATTCAGGGGGAGAATCCTTCTTGGAACAGAGATGGGCCCAGAACTGAATCAGATGAAGAGAGATAAGGTGTGATGTGGGGAAGACTATATAAAGAATGGACCCAGGGCTGCAGCAAGCACTCAACGGAATGGCCCCTCCTGGAGACACAGCCATGCATGTGCCGGCGGGCTCCGTGGCCAGCCACCTGGGGACCACGAGCCGCAGCTATTTCTATTTGACCACAGCCACTCTGGCTCTGTGCCTTGTCTTCACGGTGGCCACTATTATGGTGTTGGTCGTTCAGAGGACGGACTCCATTCCCAACTCACCTGACAACGTCCCCCTCAAAGGAGGAAATTGCTCAGAAGACCTCTTATGTATCCTGAAAAGAGCTCCATTCAAGAAGTCATGGGCCTACCTCCAAGTGGCAAAGCATCTAAACAAAACCAAGTTGTCTTGGAACAAAGATGGCATTCTCCATGGAGTCAGATATCAGGATGGGAATCTGGTGATCCAATTCCCTGGTTTGTACTTCATCATTTGCCAACTGCAGTTTCTTGTACAATGCCCAAATAATTCTGTCGATCTGAAGTTGGAGCTTCTCATCAACAAGCATATCAAAAAACAGGCCCTGGTGACAGTGTGTGAGTCTGGAATGCAAACGAAACACGTATACCAGAATCTCTCTCAATTCTTGCTGGATTACCTGCAGGTCAACACCACCATATCAGTCAATGTGGATACATTCCAGTACATAGATACAAGCACCTTTCCTCTTGAGAATGTGTTGTCCATCTTCTTATACAGTAATTCAGACTGAACAGTTTCTCTTGGCCTTCAGGAAGAAAGCGCCTCTCTACCATACAGTATTTCATCCCTCCAAACACTTGGGCAAAAAGAAAACTTTAGACCAAGACAAACTACACAGGGTATTAAATAGTATACTTCTCCTTCTGTCTCTTGGAAAGATACAGCTCCAGGGTTAAAAAGAGAGTTTTTAGTGAAGTATCTTTCAGATAGCAGGCAGGGAAGCAATGTAGTGTGGTGGGCAGAGCCCCACACAGAATCAGAAGGGATGAATGGATGTCCCAGCCCAACCACTAATTCACTGTATGGTCTTGATCTATTTCTTCTGTTTTGAGAGCCTCCAGTTAAAATGGGGCTTCAGTACCAGAGCAGCTAGCAACTCTGCCCTAATGGGAAATGAAGGGGAGCTGGGTGTGAGTGTTTACACTGTGCCCTTCACGGGATACTTCTTTTATCTGCAGATGGCCTAATGCTTAGTTGTCCAAGTCGCGATCAAGGACTCTCTCACACAGGAAACTTCCCTATACTGGCAGATACACTTGTGACTGAACCATGCCCAGTTTATGCCTGTCTGACTGTCACTCTGGCACTAGGAGGCTGATCTTGTACTCCATATGACCCCACCCCTAGGAACCCCCAGGGAAAACCAGGCTCGGACAGCCCCCTGTTCCTGAGATGGAAAGCACAAATTTAATACACCACCACAATGGAAAACAAGTTCAAAGACTTTTACTTACAGATCCTGGACAGAAAGGGCATAATGAGTCTGAAGGGCAGTCCTCCTTCTCCAGGTTACATGAGGCAGGAATAAGAAGTCAGACAGAGACAGCAAGACAGTTAACAACGTAGGTAAAGAAATAGGGTGTGGTCACTCTCAATTCACTGGCAAATGCCTGAATGGTCTGTCTGAAGGAAGCAACAGAGAAGTGGGGAATCCAGTCTGCTAGGCAGGAAAGATGCCTCTAAGTTCTTGTCTCTGGCCAGAGGTGTGGTATAGAACCAGAAACCCATATCAAGGGTGACTAAGCCCGGCTTCCGGTATGAGAAATTAAACTTGTATACAAAATGGTTGCCAAGGCAACATAAAATTATAA GAATTC(SEQ ID NO:42).

MDPGLQQALNGMAPPGDTAMHVPAGSVASHLGTTSRSYFYLTTATLALCLVFTVATIMVLVWQRTDSIPNSPDNVPLKGGNCSEDLLCILKRAPFKKSWAYLQVAKHLNKTKLSWNKDGILHGVRYQDGNLVIQFPGLYFIICQLQFLVQCPNNSVDLKLELLINKHIKKQALVTVCESGMQTKHVYQNLSQFLLDYLQVNTTISVNVDTFQYIDTSTFPLENVLSIFLYSNSD (SEQ ID NO:43).

Representative nucleotide and amino acid sequences for human CD40 areset forth in SEQ ID NO:44 (accession no. NM_001250) and SEQ ID NO:45,respectively:

TTTCCTGGGCGGGGCCAAGGCTGGGGCAGGGGAGTCAGCAGAGGCCTCGCTCGGGCGCCCAGTGGTCCTGCCGCCTGGTCTCACCTCGCTATGGTTCGTCTGCCTCTGCAGTGCGTCCTCTGGGGCTGCTTGCTGACCGCTGTCCATCCAGAACCACCCACTGCATGCAGAGAAAAACAGTACCTAATAAACAGTCAGTGCTGTTCTTTGTGCCAGCCAGGACAGAAACTGGTGAGTGACTGCACAGAGTTCACTGAAACGGAATGCCTTCCTTGCGGTGAAAGCGAATTCCTAGACACCTGGAACAGAGAGACACACTGCCACCAGCACAAATACTGCGACCCCAACCTAGGGCTTCGGGTCCAGCAGAAGGGCACCTCAGAAACAGACACCATCTGCACCTGTGAAGAAGGCTGGCACTGTACGAGTGAGGCCTGTGAGAGCTGTGTCCTGCACCGCTCATGCTCGCCCGGCTTTGGGGTCAAGCAGATTGCTACAGGGGTTTCTGATACCATCTGCGAGCCCTGCCCAGTCGGCTTCTTCTCCAATGTGTCATCTGCTTTCGAAAAATGTCACCCTTGGACAAGCTGTGAGACCAAAGACCTGGTTGTGCAACAGGCAGGCACAAACAAGACTGATGTTGTCTGTGGTCCCCAGGATCGGCTGAGAGCCCTGGTGGTGATCCCCATCATCTTCGGGATCCTGTTTGCCATCCTCTTGGTGCTGGTCTTTATCAAAAAGGTGGCCAAGAAGCCAACCAATAAGGCCCCCCACCCCAAGCAGGAACCCCAGGAGATCAATTTTCCCGACGATCTTCCTGGCTCCAACACTGCTGCTCCAGTGCAGGAGACTTTACATGGATGCCAACCGGTCACCCAGGAGGATGGCAAAGAGAGTCGCATCTCAGTGCAGGAGAGACAGTGAGGCTGCACCCACCCAGGAGTGTGGCCACGTGGGCAAACAGGCAGTTGGCCAGAGAGCCTGGTGCTGCTGCTGCTGTGGCGTGAGGGTGAGGGGCTGGCACTGACTGGGCATAGCTCCCCGCTTCTGCCTGCACCCCTGCAGTTTGAGACAGGAGACCTGGCACTGGATGCAGAAACAGTTCACCTTGAAGAACCTCTCACTTCACCCTGGAGCCCATCCAGTCTCCCAACTTGTATTAAAGACAGAGGCAGAAGTTTGGTGGTGGTGGTGTTGGGGTATGGTTTAGTAATATCCACCAGACCTTCCGATCCAGCAGTTTGGTGCCCAGAGAGGCATCATGGTGGCTTCCCTGCGCCCAGGAAGCCATATACACAGATGCCCATTGCAGCATTGTTTGTGATAGTGAACAACTGGAAGCTGCTTAACTGTCCATCAGCAGGAGACTGGCTAAATAAAATTAGAATATATTTATACAACAGAATCTCAAAAACACTGTTGAGTAAGGAAAAAAAGGCATGCTGCTGAATGATGGGTATGGAACTTTTTAAAAAAGTACATGCTTTTATGTATGTATATTGCCTATGGATATATGTATAAATACAATATGCATCATATATTGATATAACAAGGGTTCTGGAAGGGTACACAGAAAACCCACAGCTCGAAGAGTGGTGACGTCTGGGGTGGGGAAGAAGGGTCTGGGGG (SEQ ID NO:44)

MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ (SEQ IDNO:45).

Representative nucleotide and amino acid sequences for human CD70 areset forth in SEQ ID NO:46 (accession no. NM_001252) and SEQ ID NO:47,respectively:

CCAGAGAGGGGCAGGCTGGTCCCCTGACAGGTTGAAGCAAGTAGACGCCCAGGAGCCCCGGGAGGGGGCTGCAGTTTCCTTCCTTCCTTCTCGGCAGCGCTCCGCGCCCCCATCGCCCCTCCTGCGCTAGCGGAGGTGATCGCCGCGGCGATGCCGGAGGAGGGTTCGGGCTGCTCGGTGCGGCGCAGGCCCTATGGGTGCGTCCTGCGGGCTGCTTTGGTCCCATTGGTCGCGGGCTTGGTGATCTGCCTCGTGGTGTGCATCCAGCGCTTCGCACAGGCTCAGCAGCAGCTGCCGCTCGAGTCACTTGGGTGGGACGTAGCTGAGCTGCAGCTGAATCACACAGGACCTCAGCAGGACCCCAGGCTATACTGGCAGGGGGGCCCAGCACTGGGCCGCTCCTTCCTGCATGGACCAGAGCTGGACAAGGGGCAGCTACGTATCCATCGTGATGGCATCTACATGGTACACATCCAGGTGACGCTGGCCATCTGCTCCTCCACGACGGCCTCCAGGCACCACCCCACCACCCTGGCCGTGGGAATCTGCTCTCCCGCCTCCCGTAGCATCAGCCTGCTGCGTCTCAGCTTCCACCAAGGTTGTACCATTGCCTCCCAGCGCCTGACGCCCCTGGCCCGAGGGGACACACTCTGCACCAACCTCACTGGGACACTTTTGCCTTCCCGAAACACTGATGAGACCTTCTTTGGAGTGCAGTGGGTGCGCCCCTGACCACTGCTGCTGATTAGGGTTTTTTAAATTTTATTTTATTTTATTTAAGTTCAAGAGAAAAAGTGTACACACAGGGGCCACCCGGGGTTGGGGTGGGAGTGTGGTGGGGGGTAGTGGTGGCAGGACAAGAGAAGGCATTGAGCTTTTTCTTTCATTTTCCTATTAAAAAATACAAAAATCA (SEQ ID NO:46).

MPEEGSGCSVRRRPYGCVLRAALVPLVAGLVICLVVCIQRFAQAQQQLPLESLGWDVAELQLNHTGPQQDPRLYWQGGPALGRSFLHGPELDKGQLRIHRDGIYMVHIQVTLAICSSTTASRHHPTTLAVGICSPASRSISLLRLSFHQGCTIASQRLTPLARGDTLCTNLTGTLLPSRNTDETFFGVQWVRP(SEQ ID  NO: 47).

Representative nucleotide and amino acid sequences for human LIGHT areset forth in SEQ ID NO:48 (accession no. CR541854) and SEQ ID NO:49,respectively:

ATGGAGGAGAGTGTCGTACGGCCCTCAGTGTTTGTGGTGGATGGACAGACCGACATCCCATTCACGAGGCTGGGACGAAGCCACCGGAGACAGTCGTGCAGTGTGGCCCGGGTGGGTCTGGGTCTCTTGCTGTTGCTGATGGGGGCCGGGCTGGCCGTCCAAGGCTGGTTCCTCCTGCAGCTGCACTGGCGTCTAGGAGAGATGGTCACCCGCCTGCCTGACGGACCTGCAGGCTCCTGGGAGCAGCTGATACAAGAGCGAAGGTCTCACGAGGTCAACCCAGCAGCGCATCTCACAGGGGCCAACTCCAGCTTGACCGGCAGCGGGGGGCCGCTGTTATGGGAGACTCAGCTGGGCCTGGCCTTCCTGAGGGGCCTCAGCTACCACGATGGGGCCCTTGTGGTCACCAAAGCTGGCTACTACTACATCTACTCCAAGGTGCAGCTGGGCGGTGTGGGCTGCCCGCTGGGCCTGGCCAGCACCATCACCCACGGCCTCTACAAGCGCACACCCCGCTACCCCGAGGAGCTGGAGCTGTTGGTCAGCCAGCAGTCACCCTGCGGACGGGCCACCAGCAGCTCCCGGGTCTGGTGGGACAGCAGCTTCCTGGGTGGTGTGGTACACCTGGAGGCTGGGGAGGAGGTGGTCGTCCGTGTGCTGGATGAACGCCTGGTTCGACTGCGTGATGGTACCCGGTCTTACTTCGGGGCTTTCATGGTGTGA (SEQ ID NO:48).

MEESVVRPSVFVVDGQTDIPFTRLGRSHRRQSCSVARVGLGLLLLLMGAGLAVQGWFLLQLHWRLGEMVTRLPDGPAGSWEQLIQERRSHEVNPAAHLTGANSSLTGSGGPLLWETQLGLAFLRGLSYHDGALWTKAGYYYlYSKVQLGGVGCPLGLASTITHGLYKRTPRYPEELELLVSQQSPCGRATSSSRVWWDSSFLGGVVHLEAGEEVVVRVLDERLVRLRDGTRSYFGAFMV (SEQ ID NO :49).

In various embodiments, the present invention provides for variantscomprising any of the sequences described herein, for instance, asequence having at least about 60%, or at least about 61%, or at leastabout 62%, or at least about 63%, or at least about 64%, or at leastabout 65%, or at least about 66%, or at least about 67%, or at leastabout 68%, or at least about 69%, or at least about 70%, or at leastabout 71%, or at least about 72%, or at least about 73%, or at leastabout 74%, or at least about 75%, or at least about 76%, or at leastabout 77%, or at least about 78%, or at least about 79%, or at leastabout 80%, or at least about 81%, or at least about 82%, or at leastabout 83%, or at least about 84%, or at least about 85%, or at leastabout 86%, or at least about 87%, or at least about 88%, or at leastabout 89%, or at least about 90%, or at least about 91%, or at leastabout 92%, or at least about 93%, or at least about 94%, or at leastabout 95%, or at least about 96%, or at least about 97%, or at leastabout 98%, or at least about 99%) sequence identity with any of thesequences disclosed herein (for example, SEQ ID NOS: 1-13 and 38-49).

In various embodiments, the present invention provides for an amino acidsequence having one or more amino acid mutations relative any of theprotein sequences described herein. In some embodiments, the one or moreamino acid mutations may be independently selected from conservative ornon-conservative substitutions, insertions, deletions, and truncationsas described herein.

Checkpoint Blockade / Blockage of Tumor Immunosuppression

Some human tumors can be eliminated by a patient’s immune system. Forexample, administration of a monoclonal antibody targeted to an immune“checkpoint” molecule can lead to complete response and tumor remission.A mode of action of such antibodies is through inhibition of an immuneregulatory molecule that the tumors have co-opted as protection from ananti-tumor immune response. By inhibiting these “checkpoint” molecules(e.g., with an antagonistic antibody), a patient’s CD8+ T cells may beallowed to proliferate and destroy tumor cells.

For example, administration of a monoclonal antibody targeted to by wayof example, without limitation, CTLA-4 or PD-1 can lead to completeresponse and tumor remission. The mode of action of such antibodies isthrough inhibition of CTLA-4 or PD-1 that the tumors have co-opted asprotection from an anti-tumor immune response. By inhibiting these“checkpoint” molecules (e.g., with an antagonistic antibody), apatient’s CD8+ T cells may be allowed to proliferate and destroy tumorcells.

Thus, the vectors provided herein can be used in combination with one ormore blocking antibodies targeted to an immune “checkpoint’ molecule.For instance, in some embodiments, the vectors provided herein can beused in combination with one or more blocking antibodies targeted to amolecule such as CTLA-4 or PD-1. For example, the vectors providedherein may be used in combination with an agent that blocks, reducesand/or inhibits PD-1 and PD-L1 or PD-L2 and/or the binding of PD-1 withPD-L1 or PD-L2 (by way of non-limiting example, one or more of nivolumab(ONO-4538/BMS-936558, MDX1106, OPDIVO, BRISTOL MYERS SQUIBB),pembrolizumab (KEYTRUDA, Merck), pidilizumab (CT-011, CURE TECH),MK-3475 (MERCK), BMS 936559 (BRISTOL MYERS SQUIBB), MPDL328OA (ROCHE)).In an embodiment, the vectors provided herein may be used in combinationwith an agent that blocks, reduces and/or inhibits the activity ofCTLA-4 and/or the binding of CTLA-4 with one or more receptors (e.g.CD80, CD86, AP2M1, SHP-2, and PPP2R5A). For instance, in someembodiments, the immune-modulating agent is an antibody such as, by wayof non-limitation, ipilimumab (MDX-010, MDX-101, Yervoy, BMS) and/ortremelimumab (Pfizer). Blocking antibodies against these molecules canbe obtained from, for example, Bristol Myers Squibb (New York, NY),Merck (Kenilworth, NJ), MedImmune (Gaithersburg, MD), and Pfizer (NewYork, NY).

Further, the vectors provided herein can be used in combination with oneor more blocking antibodies targeted to an immune “checkpoint” moleculesuch as for example, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4,CD160 (also referred to as BY55), CGEN-15049, CHK 1 and CHK2 kinases,A2aR, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), GITR, GITRL,galectin-9, CD244, CD160, TIGIT, SIRPα, ICOS, CD172a, and TMIGD2 andvarious B-7 family ligands (including, but are not limited to, B7-1,B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7).

Vectors and Host Cells

The present disclosure provides nucleic acid constructs that encode avaccine protein fusion protein (e.g., a gp96-Ig fusion protein).Further, the present disclosure, provides nucleic acid constructs thatencode a vaccine protein fusion protein (e.g., a gp96-Ig fusionprotein), and a T cell costimulatory fusion protein that can beexpressed in prokaryotic and eukaryotic cells. For example, the presentdisclosure provides expression vectors (e.g., DNA- or RNA-based vectors)containing nucleotide sequences that encode a vaccine protein fusion(e.g., a gp96-Ig fusion). For example, the present disclosure providesexpression vectors (e.g., DNA- or RNA-based vectors) containingnucleotide sequences that encode a vaccine protein fusion (e.g., agp96-Ig fusion), and a T cell costimulatory fusion protein (e.g.,OX40L-Ig or a portion thereof that binds specifically to OX40, ICOSL-Igor a portion thereof that binds specifically to ICOS, 4-1BBL-Ig, or aportion thereof that binds specifically to 4-1BBR, CD40L-lg, or aportion thereof that binds specifically to CD40, CD70-lg, or a portionthereof that binds specifically to CD27, TL1A-lg or a portion thereofthat binds specifically to TNFRSF25, or GITRL-Ig or a portion thereofthat binds specifically to GITR). In addition, this document providesmethods for making the vectors described herein, as well as methods forintroducing the vectors into appropriate host cells for expression ofthe encoded polypeptides. In general, the methods provided hereininclude constructing nucleic acid sequences encoding a vaccine proteinfusion protein (e.g., a gp96-Ig fusion protein) and a T cellcostimulatory fusion protein, cloning the sequences encoding the fusionproteins into an expression vector. The expression vector can beintroduced into host cells or incorporated into virus particles, eitherof which can be administered to a subject to, for example, treat canceror infection. For example, gp96-Ig based vaccines can be generated tostimulate antigen specific immune responses against individual antigensexpressed by simian immunodeficiency virus, human immunodeficiencyvirus, hepatitis C virus and malaria. Immune responses to these vaccinesmay be enhanced through co-expression of a T cell costimulatory fusionprotein by the gp96-Ig vector.

cDNA or DNA sequences encoding a vaccine protein fusion (e.g., a gp96-Igfusion) and a T cell costimulatory fusion protein can be obtained (and,if desired, modified) using conventional DNA cloning and mutagenesismethods, DNA amplification methods, and/or synthetic methods. Ingeneral, a sequence encoding a vaccine protein fusion protein (e.g., agp96-Ig fusion protein) and/or a T cell costimulatory fusion protein canbe inserted into a cloning vector for genetic modification andreplication purposes prior to expression. Each coding sequence can beoperably linked to a regulatory element, such as a promoter, forpurposes of expressing the encoded protein in suitable host cells invitro and in vivo.

Expression vectors can be introduced into host cells for producingsecreted vaccine proteins (e.g., gp96-Ig) and T cell costimulatoryfusion proteins. There are a variety of techniques available forintroducing nucleic acids into viable cells. Techniques suitable for thetransfer of nucleic acid into mammalian cells in vitro include the useof liposomes, electroporation, microinjection, cell fusion,polymer-based systems, DEAE-dextran, viral transduction, the calciumphosphate precipitation method, etc. For in vivo gene transfer, a numberof techniques and reagents may also be used, including liposomes;natural polymer-based delivery vehicles, such as chitosan and gelatin;viral vectors are also suitable for in vivo transduction. In somesituations it is desirable to provide a targeting agent, such as anantibody or ligand specific for a cell surface membrane protein. Whereliposomes are employed, proteins which bind to a cell surface membraneprotein associated with endocytosis may be used for targeting and/or tofacilitate uptake, e.g., capsid proteins or fragments thereof tropic fora particular cell type, antibodies for proteins which undergointernalization in cycling, proteins that target intracellularlocalization and enhance intracellular half-life. The technique ofreceptor-mediated endocytosis is described, for example, by Wu et al.,J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl.Acad. Sci. USA 87, 3410-3414 (1990).

Where appropriate, gene delivery agents such as, e.g., integrationsequences can also be employed. Numerous integration sequences are knownin the art (see, e.g., Nunes-Duby et al., Nucleic Acids Res. 26:391-406,1998; Sadwoski, J. Bacteriol., 165:341-357, 1986; Bestor, Cell,122(3):322-325, 2005; Plasterk et al., TIG 15:326-332, 1999; Kootstra etal., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). These includerecombinases and transposases. Examples include Cre (Sternberg andHamilton, J. Mol. Biol., 150:467-486, 1981), lambda (Nash, Nature, 247,543-545, 1974), Flp (Broach, et al., Cell, 29:227-234, 1982), R(Matsuzaki, et al., J. Bacteriology, 172:610-618, 1990), cpC31 (see,e.g., Groth et al., J. Mol. Biol. 335:667-678, 2004), sleeping beauty,transposases of the mariner family (Plasterk et al., supra), andcomponents for integrating viruses such as AAV, retroviruses, andantiviruses having components that provide for virus integration such asthe LTR sequences of retroviruses or lentivirus and the ITR sequences ofAAV (Kootstra et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003).

Cells may be cultured in vitro or genetically engineered, for example.Host cells can be obtained from normal or affected subjects, includinghealthy humans, cancer patients, and patients with an infectiousdisease, private laboratory deposits, public culture collections such asthe American Type Culture Collection, or from commercial suppliers.

Cells that can be used for production and secretion of gp96-Ig fusionproteins and T cell costimulatory fusion proteins in vivo include,without limitation, epithelial cells, endothelial cells, keratinocytes,fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, B lymphocytes, monocytes, macrophages, neutrophils,eosinophils, megakaryocytes, or granulocytes, various stem or progenitorcells, such as hematopoietic stem or progenitor cells (e.g., as obtainedfrom bone marrow), umbilical cord blood, peripheral blood, fetal liver,etc., and tumor cells (e.g., human tumor cells). The choice of cell typedepends on the type of tumor or infectious disease being treated orprevented, and can be determined by one of skill in the art.

Different host cells have characteristic and specific mechanisms forpost-translational processing and modification of proteins. A host cellmay be chosen which modifies and processes the expressed gene productsin a specific fashion similar to the way the recipient processes itsheat shock proteins (hsps). For the purpose of producing large amountsof gp96-Ig, it can be preferable that the type of host cell has beenused for expression of heterologous genes, and is reasonably wellcharacterized and developed for large-scale production processes. Insome embodiments, the host cells are autologous to the patient to whomthe present fusion or recombinant cells secreting the present fusionproteins are subsequently administered.

In some embodiments, an expression construct as provided herein can beintroduced into an antigenic cell. As used herein, antigenic cells caninclude preneoplastic cells that are infected with a cancer-causinginfectious agent, such as a virus, but that are not yet neoplastic, orantigenic cells that have been exposed to a mutagen or cancer-causingagent, such as a DNA-damaging agent or radiation, for example. Othercells that can be used are preneoplastic cells that are in transitionfrom a normal to a neoplastic form as characterized by morphology orphysiological or biochemical function.

Typically, the cancer cells and preneoplastic cells used in the methodsprovided herein are of mammalian origin. Mammals contemplated includehumans, companion animals (e.g., dogs and cats), livestock animals(e.g., sheep, cattle, goats, pigs and horses), laboratory animals (e.g.,mice, rats and rabbits), and captive or free wild animals.

In some embodiments, cancer cells (e.g., human tumor cells) can be usedin the methods described herein. The cancer cells provide antigenicpeptides that become associated non-covalently with the expressedgp96-Ig fusion proteins. Cell lines derived from a preneoplastic lesion,cancer tissue, or cancer cells also can be used, provided that the cellsof the cell line have at least one or more antigenic determinant incommon with the antigens on the target cancer cells. Cancer tissues,cancer cells, cells infected with a cancer-causing agent, otherpreneoplastic cells, and cell lines of human origin can be used. Cancercells excised from the patient to whom ultimately the fusion proteinsultimately are to be administered can be particularly useful, althoughallogeneic cells also can be used. In some embodiments, a cancer cellcan be from an established tumor cell line such as, without limitation,an established non-small cell lung carcinoma (NSCLC), bladder cancer,melanoma, ovarian cancer, renal cell carcinoma, prostate carcinoma,sarcoma, breast carcinoma, squamous cell carcinoma, head and neckcarcinoma, hepatocellular carcinoma, pancreatic carcinoma, or coloncarcinoma cell line.

In various embodiments, the present fusion proteins allow for both thecostimulation T cell and the presentation of various tumor cellantigens. For instance, in some embodiments, the present vaccine proteinfusions (e.g., gp96 fusions) chaperone these various tumor antigens. Invarious embodiments, the tumor cells secrete a variety of antigens.Illustrative, but non-limiting, antigens that can be secreted are:MART-⅟Melan-A, gp100, Dipeptidyl peptidase IV (DPPIV), adenosinedeaminase-binding protein (ADAbp), cyclophilin b, Colorectal associatedantigen (CRC)-0017-1A/GA733, Carcinoembryonic Antigen (CEA) and itsimmunogenic epitopes CAP-1 and CAP-2, etv6, aml1, Prostate SpecificAntigen (PSA) and its immunogenic epitopes PSA-1, PSA-2, and PSA-3,prostate-specific membrane antigen (PSMA), T-cell receptor/CD3-zetachain, MAGE-family of tumor antigens (e.g., MAGE-A1, MAGE-A2, MAGE-A3,MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10,MAGE-A11, MAGE-A12, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4(MAGE-B4), MAGE-C1, MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5), GAGE-family oftumor antigens (e.g., GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6,GAGE-7, GAGE-8, GAGE-9), BAGE, RAGE, LAGE-1, NAG, GnT-V, MUM-1, CDK4,tyrosinase, p53, MUC family, HER2/neu, p21ras, RCAS1, α-fetoprotein,E-cadherin, a-catenin, β-catenin and γ-catenin, p120ctn, gp100 Pmel117,PRAME, NY-ESO-1, cdc27, adenomatous polyposis coli protein (APC),fodrin, Connexin 37, Ig-idiotype, p15, gp75, GM2 and GD2 gangliosides,viral products such as human papilloma virus proteins, Smad family oftumor antigens, Imp-1, NA, EBV-encoded nuclear antigen (EBNA)-1, brainglycogen phosphorylase, SSX-1, SSX-2 (HOM-MEL-40), SSX-1, SSX-4, SSX-5,SCP-1 CT-7, c-erbB-2, CD19, CD20, CD22, CD30, CD33, CD37, CD56, CD70,CD74, CD138, AGS16, MUC1, GPNMB, Ep-CAM, PD-L1, PD-L2, PMSA, bladdercancer antigens such as ACTL8, ADAM22, ADAM23, ATAD2, ATAD2B, BIRC5,CASC5, CEP290, CEP55, CTAGE5, DCAF12, DDX5, FAM133A, IL13RA2, IMP3,KIAA0100, MAGEA11, MAGEA3, MAGEA6, MPHOSPH10, ODF2, ODF2L, OIP5, PBK,RQCD1, SPAG1, SPAG4, SPAG9, TMEFF1, TTK, and prostate cancer antigenssuch as PRAME, BIRC5, CEP55, ATAD2, ODF2, KIAA0100, SPAG9, GPATCH2,ATAD2B, CEP290, SPAG1, ODF2L, CTAGE5, DDX5, DCAF12, IMP3. In someembodiments, the antigens are human endogenous retroviral antigens.Illustrative antigens can also include antigens from human endogenousretroviruses which include, but are not limited to, epitopes derivedfrom at least a portion of Gag, at least a portion of Tat, at least aportion of Rev, a least a portion of Nef, and at least a portion ofgp160.

Further, in some embodiments, the present vaccine protein fusions (e.g.,gp96 fusions) provide for an adjuvant effect that further allows theimmune system of a patient, when used in the various methods describedherein, to be activated against a disease of interest.

Both prokaryotic and eukaryotic vectors can be used for expression ofthe vaccine protein (e.g., gp96-Ig) and T cell costimulatory fusionproteins in the methods provided herein. Prokaryotic vectors includeconstructs based on E. coli sequences (see, e.g., Makrides, MicrobiolRev 1996, 60:512-538). Non-limiting examples of regulatory regions thatcan be used for expression in E. coli include lac, trp, Ipp, phoA, recA,tac, T3, T7 and λP_(L). Non-limiting examples of prokaryotic expressionvectors may include the Agt vector series such as Agt11 (Huynh et al.,in “DNA Cloning Techniques, Vol. I: A Practical Approach,” 1984, (D.Glover, ed.), pp. 49-78, IRL Press, Oxford), and the pET vector series(Studier et al., Methods Enzymol 1990, 185:60-89). Prokaryotichost-vector systems cannot perform much of the post-translationalprocessing of mammalian cells, however. Thus, eukaryotic host- vectorsystems may be particularly useful.

A variety of regulatory regions can be used for expression of thevaccine protein (e.g., gp96-Ig) and T cell costimulatory fusions inmammalian host cells. For example, the SV40 early and late promoters,the cytomegalovirus (CMV) immediate early promoter, and the Rous sarcomavirus long terminal repeat (RSV-LTR) promoter can be used. Induciblepromoters that may be useful in mammalian cells include, withoutlimitation, promoters associated with the metallothionein II gene, mousemammary tumor virus glucocorticoid responsive long terminal repeats(MMTV-LTR), the β-interferon gene, and the hsp70 gene (see, Williams etal., Cancer Res 1989, 49:2735-42; and Taylor et al., Mol Cell Biol 1990,10:165-75). Heat shock promoters or stress promoters also may beadvantageous for driving expression of the fusion proteins inrecombinant host cells.

In an embodiment, the present invention contemplates the use ofinducible promoters capable of effecting high level of expressiontransiently in response to a cue. Illustrative inducible expressioncontrol regions include those comprising an inducible promoter that isstimulated with a cue such as a small molecule chemical compound.Particular examples can be found, for example, in U.S. Pat. Nos.5,989,910, 5,935,934, 6,015,709, and 6,004,941, each of which isincorporated herein by reference in its entirety.

Animal regulatory regions that exhibit tissue specificity and have beenutilized in transgenic animals also can be used in tumor cells of aparticular tissue type: the elastase I gene control region that isactive in pancreatic acinar cells (Swift et al., Cell 1984, 38:639-646;Ornitz et al., Cold Spring Harbor Symp Quant Biol 1986, 50:399-409; andMacDonald, Hepatology 1987, 7:425-515); the insulin gene control regionthat is active in pancreatic beta cells (Hanahan, Nature 1985,315:115-122), the immunoglobulin gene control region that is active inlymphoid cells (Grosschedl et al., Cell 1984, 38:647-658; Adames et al.,Nature 1985, 318:533-538; and Alexander et al., Mol Cell Biol 1987,7:1436-1444), the mouse mammary tumor virus control region that isactive in testicular, breast, lymphoid and mast cells (Leder et al.,Cell 1986, 45:485-495), the albumin gene control region that is activein liver (Pinkert et al., Genes Devel, 1987, 1:268-276), thealpha-fetoprotein gene control region that is active in liver (Krumlaufet al., Mol Cell Biol 1985, 5:1639-1648; and Hammer et al., Science1987, 235:53-58); the alpha 1-antitrypsin gene control region that isactive in liver (Kelsey et al., Genes Devel 1987, 1:161-171), thebeta-globin gene control region that is active in myeloid cells (Mogramet al., Nature 1985, 315:338-340; and Kollias et al., Cell 1986,46:89-94); the myelin basic protein gene control region that is activein oligodendrocyte cells in the brain (Readhead et al., Cell 1987,48:703-712); the myosin light chain-2 gene control region that is activein skeletal muscle (Sani, Nature 1985, 314:283-286), and thegonadotropic releasing hormone gene control region that is active in thehypothalamus (Mason et al., Science 1986, 234:1372-1378).

An expression vector also can include transcription enhancer elements,such as those found in SV40 virus, Hepatitis B virus, cytomegalovirus,immunoglobulin genes, metallothionein, and β-actin (see, Bittner et al.,Meth Enzymol 1987, 153:516-544; and Gorman, Curr Op Biotechnol 1990,1:36-47). In addition, an expression vector can contain sequences thatpermit maintenance and replication of the vector in more than one typeof host cell, or integration of the vector into the host chromosome.Such sequences include, without limitation, to replication origins,autonomously replicating sequences (ARS), centromere DNA, and telomereDNA.

In addition, an expression vector can contain one or more selectable orscreenable marker genes for initially isolating, identifying, ortracking host cells that contain DNA encoding fusion proteins asdescribed herein. For long term, high yield production of gp96-Ig and Tcell costimulatory fusion proteins, stable expression in mammalian cellscan be useful. A number of selection systems can be used for mammaliancells. For example, the Herpes simplex virus thymidine kinase (Wigler etal., Cell 1977, 11:223), hypoxanthine-guanine phosphoribosyltransferase(Szybalski and Szybalski, Proc Natl Acad Sci USA 1962, 48:2026), andadenine phosphoribosyltransferase (Lowy et al., Cell 1980, 22:817) genescan be employed in tk⁻, hgprt⁻, or aprt⁻ cells, respectively. Inaddition, antimetabolite resistance can be used as the basis ofselection for dihydrofolate reductase (dhfr), which confers resistanceto methotrexate (Wigler et al., Proc Natl Acad Sci USA 1980, 77:3567;O′Hare et al., Proc Natl Acad Sci USA 1981, 78:1527); gpt, which confersresistance to mycophenolic acid (Mulligan and Berg, Proc Natl Acad SciUSA 1981, 78:2072); neomycin phosphotransferase (neo), which confersresistance to the aminoglycoside G-418 (Colberre-Garapin et al., J MolBiol 1981, 150:1); and hygromycin phosphotransferase (hyg), whichconfers resistance to hygromycin (Santerre et al., Gene 1984, 30:147).Other selectable markers such as histidinol and Zeocin™ also can beused.

Useful mammalian host cells include, without limitation, cells derivedfrom humans, monkeys, and rodents (see, for example, Kriegler in “GeneTransfer and Expression: A Laboratory Manual,” 1990, New York, Freeman &Co.). These include monkey kidney cell lines transformed by SV40 (e.g.,COS-7, ATCC CRL 1651); human embryonic kidney lines (e.g., 293,293-EBNA, or 293 cells subcloned for growth in suspension culture,Graham et al., J Gen Virol 1977, 36:59); baby hamster kidney cells(e.g., BHK, ATCC CCL 10); Chinese hamster ovary-cells-DHFR (e.g., CHO,Urlaub and Chasin, Proc Natl Acad Sci USA 1980, 77:4216); mouse sertolicells (Mather, Biol Reprod 1980, 23:243-251); mouse fibroblast cells(e.g., NIH-3T3), monkey kidney cells (e.g., CV1 ATCC CCL 70); Africangreen monkey kidney cells. (e.g., VERO-76, ATCC CRL-1587); humancervical carcinoma cells (e.g., HELA, ATCC CCL 2); canine kidney cells(e.g., MDCK, ATCC CCL 34); buffalo rat liver cells (e.g., BRL 3A, ATCCCRL 1442); human lung cells (e.g., W138, ATCC CCL 75); human liver cells(e.g., Hep G2, HB 8065); and mouse mammary tumor cells (e.g., MMT060562, ATCC CCL51). Illustrative cancer cell types for expressing thefusion proteins described herein include mouse fibroblast cell line,NIH3T3, mouse Lewis lung carcinoma cell line, LLC, mouse mastocytomacell line, P815, mouse lymphoma cell line, EL4 and its ovalbumintransfectant, E.G7, mouse melanoma cell line, B16F10, mouse fibrosarcomacell line, MC57, human small cell lung carcinoma cell lines, SCLC#2 andSCLC#7, human lung adenocarcinoma cell line, e.g., AD100, and humanprostate cancer cell line, e.g., PC-3.

A number of viral-based expression systems also can be used withmammalian cells to produce gp96-Ig and T cell costimulatory fusionproteins. Vectors using DNA virus backbones have been derived fromsimian virus 40 (SV40) (Hamer et al., Cell 1979, 17:725), adenovirus(Van Doren et al., Mol Cell Biol 1984, 4:1653), adeno-associated virus(McLaughlin et al., J Virol 1988, 62:1963), and bovine papillomas virus(Zinn et al., Proc Natl Acad Sci USA 1982, 79:4897). When an adenovirusis used as an expression vector, the donor DNA sequence may be ligatedto an adenovirus transcription/translation control complex, e.g., thelate promoter and tripartite leader sequence. This fusion gene may thenbe inserted in the adenovirus genome by in vitro or in vivorecombination. Insertion in a non-essential region of the viral genome(e.g., region E1 or E3) can result in a recombinant virus that is viableand capable of expressing heterologous products in infected hosts. (See,e.g., Logan and Shenk, Proc Natl Acad Sci USA 1984, 81:3655-3659).

In some embodiments, an adenovirus expression vector comprising aneffective amount of a composition that comprises a nucleotide sequenceencoding a secretable vaccine protein (e.g., without limitation gp96-Ig)is used.

In some embodiments, the adenovirus expression vector comprises aneffective amount of a composition that comprises a first nucleotidesequence encoding a secretable vaccine protein (e.g., without limitationgp96-Ig) and and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40).

In some embodiments, the adenovirus expression vector comprises aneffective amount of a composition that comprises a first nucleotidesequence encoding a secretable vaccine protein (e.g., without limitationgp96-Ig) and and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40) and an effective amount of abiological cell comprising an adenovirus expression vector thatcomprises a first nucleotide sequence encoding a secretable vaccineprotein (e.g., without limitation gp96-Ig), and a second nucleotidesequence encoding a T cell costimulatory fusion protein (e.g., withoutlimitation OX40L-Ig, or a portion thereof that binds to OX40).

In some embodiments, the present invention provides a method fortreating a tumor in a subject in need thereof, comprising administeringto a subject in need thereof a combination therapy of (1) intratumorallydelivery of an effective amount of a composition comprising anadenovirus expression vector that comprises a first nucleotide sequenceencoding a secretable vaccine protein (e.g., without limitationgp96-Ig), and a second nucleotide sequence encoding a T cellcostimulatory fusion protein (e.g., without limitation OX40L-Ig, or aportion thereof that binds to OX40) and (2) an effective amount of abiological cell comprising an adenovirus expression vector thatcomprises a first nucleotide sequence encoding a secretable vaccineprotein (e.g., without limitation gp96-Ig), and a second nucleotidesequence encoding a T cell costimulatory fusion protein (e.g., withoutlimitation OX40L-Ig, or a portion thereof that binds to OX40), whereinthe T cell costimulatory fusion protein enhances activation ofantigen-specific T cells when administered to the subject.

Bovine papillomavirus (BPV) can infect many higher vertebrates,including man, and its DNA replicates as an episome. A number of shuttlevectors have been developed for recombinant gene expression which existas stable, multicopy (20-300 copies/cell) extrachromosomal elements inmammalian cells. Typically, these vectors contain a segment of BPV DNA(the entire genome or a 69% transforming fragment), a promoter with abroad host range, a polyadenylation signal, splice signals, a selectablemarker, and “poisonless” plasmid sequences that allow the vector to bepropagated in E. coli. Following construction and amplification inbacteria, the expression gene constructs are transfected into culturedmammalian cells by, for example, calcium phosphate coprecipitation. Forthose host cells that do not manifest a transformed phenotype, selectionof transformants is achieved by use of a dominant selectable marker,such as histidinol and G418 resistance.

Alternatively, the vaccinia 7.5 K promoter can be used. (See, e.g.,Mackett et al., Proc Natl Acad Sci USA 1982, 79:7415-7419; Mackett etal., J Virol 1984, 49:857-864; and Panicali et al., Proc Natl Acad SciUSA 1982, 79:4927-4931.) In cases where a human host cell is used,vectors based on the Epstein-Barr virus (EBV) origin (OriP) and EBVnuclear antigen 1 (EBNA-1; a trans-acting replication factor) can beused. Such vectors can be used with a broad range of human host cells,e.g., EBO-pCD (Spickofsky et al., DNA Prot Eng Tech 1990, 2:14-18); pDR2and ADR2 (available from Clontech Laboratories).

Gp96-Ig and T cell costimulatory fusion proteins also can be made withretrovirus-based expression systems. Retroviruses, such as Moloneymurine leukemia virus, can be used since most of the viral gene sequencecan be removed and replaced with exogenous coding sequence while themissing viral functions can be supplied in trans. In contrast totransfection, retroviruses can efficiently infect and transfer genes toa wide range of cell types including, for example, primary hematopoieticcells. Moreover, the host range for infection by a retroviral vector canbe manipulated by the choice of envelope used for vector packaging.

For example, a retroviral vector can comprise a 5′ long terminal repeat(LTR), a 3′ LTR, a packaging signal, a bacterial origin of replication,and a selectable marker. The gp96-Ig fusion protein coding sequence, forexample, can be inserted into a position between the 5′ LTR and 3′ LTR,such that transcription from the 5′ LTR promoter transcribes the clonedDNA. The 5′ LTR contains a promoter (e.g., an LTR promoter), an Rregion, a U5 region, and a primer binding site, in that order.Nucleotide sequences of these LTR elements are well known in the art. Aheterologous promoter as well as multiple drug selection markers alsocan be included in the expression vector to facilitate selection ofinfected cells. See, McLauchlin et al., Prog Nucleic Acid Res Mol Biol1990, 38:91-135; Morgenstern et al., Nucleic Acid Res 1990,18:3587-3596; Choulika et al., J Virol 1996, 70:1792-1798; Boesen etal., Biotherapy 1994, 6:291-302; Salmons and Gunzberg, Human Gene Ther1993, 4:129-141; and Grossman and Wilson, Curr Opin Genet Devel 1993,3:110-114.

Any of the cloning and expression vectors described herein may besynthesized and assembled from known DNA sequences using techniques thatare known in the art. The regulatory regions and enhancer elements canbe of a variety of origins, both natural and synthetic. Some vectors andhost cells may be obtained commercially. Non-limiting examples of usefulvectors are described in Appendix 5 of Current Protocols in MolecularBiology, 1988, ed. Ausubel et al., Greene Publish. Assoc. & WileyInterscience, which is incorporated herein by reference; and thecatalogs of commercial suppliers such as Clontech Laboratories,Stratagene Inc., and Invitrogen, Inc.

Methods of Treating

An expression vector as provided herein can be incorporated into acomposition for administration to a subject (e.g., a research animal ora mammal, such as a human, having a clinical condition such as cancer oran infection). For example, an expression vector can be administered toa subject for the treatment of cancer. Thus, this document providesmethods for treating clinical conditions such as cancer with theexpression vectors provided herein. The methods can includeadministering to a subject an expression vector, a cell containing theexpression vector, or a virus or virus-like particle containing theexpression vector, under conditions wherein the progression or a symptomof the clinical condition in the subject is reduced in a therapeuticmanner.

As described herein, the expression vector(s) can be administeredintratumorally to a subject. Optionally, the subject may further beadministered a biological cell comprising the expression vector(s).

In various embodiments, the present invention pertains to cancers and/ortumors; for example, the treatment or prevention of cancers and/ortumors. Cancers or tumors refer to an uncontrolled growth of cellsand/or abnormal increased cell survival and/or inhibition of apoptosiswhich interferes with the normal functioning of the bodily organs andsystems. Included are benign and malignant cancers, polyps, hyperplasia,as well as dormant tumors or micrometastases. Also, included are cellshaving abnormal proliferation that is not impeded by the immune system(e.g., virus infected cells). The cancer may be a primary cancer or ametastatic cancer. The primary cancer may be an area of cancer cells atan originating site that becomes clinically detectable, and may be aprimary tumor. In contrast, the metastatic cancer may be the spread of adisease from one organ or part to another non-adjacent organ or part.The metastatic cancer may be caused by a cancer cell that acquires theability to penetrate and infiltrate surrounding normal tissues in alocal area, forming a new tumor, which may be a local metastasis. Thecancer may also be caused by a cancer cell that acquires the ability topenetrate the walls of lymphatic and/or blood vessels, after which thecancer cell is able to circulate through the bloodstream (thereby beinga circulating tumor cell) to other sites and tissues in the body. Thecancer may be due to a process such as lymphatic or hematogeneousspread. The cancer may also be caused by a tumor cell that comes to restat another site, re-penetrates through the vessel or walls, continues tomultiply, and eventually forms another clinically detectable tumor. Thecancer may be this new tumor, which may be a metastatic (or secondary)tumor.

The cancer may be caused by tumor cells that have metastasized, whichmay be a secondary or metastatic tumor. The cells of the tumor may belike those in the original tumor. As an example, if a breast cancer orcolon cancer metastasizes to the liver, the secondary tumor, whilepresent in the liver, is made up of abnormal breast or colon cells, notof abnormal liver cells. The tumor in the liver may thus be a metastaticbreast cancer or a metastatic colon cancer, not liver cancer.

The cancer may have an origin from any tissue. The cancer may originatefrom melanoma, colon, breast, or prostate, and thus may be made up ofcells that were originally skin, colon, breast, or prostate,respectively. The cancer may also be a hematological malignancy, whichmay be lymphoma. The cancer may invade a tissue such as liver, lung,bladder, or intestinal.

Illustrative cancers that may be treated include, but are not limitedto, carcinomas, e.g., various subtypes, including, for example,adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, andtransitional cell carcinoma), sarcomas (including, for example, bone andsoft tissue), leukemias (including, for example, acute myeloid, acutelymphoblastic, chronic myeloid, chronic lymphocytic, and hairy cell),lymphomas and myelomas (including, for example, Hodgkin and non-Hodgkinlymphomas, light chain, non-secretory, MGUS, and plasmacytomas), andcentral nervous system cancers (including, for example, brain (e.g.,gliomas (e.g,. astrocytoma, oligodendroglioma, and ependymoma),meningioma, pituitary adenoma, and neuromas, and spinal cord tumors(e.g., meningiomas and neurofibroma).

Representative cancers and/or tumors of the present invention include,but are not limited to, a basal cell carcinoma, biliary tract cancer;bladder cancer; bone cancer; brain and central nervous system cancer;breast cancer; cancer of the peritoneum; cervical cancer;choriocarcinoma; colon and rectum cancer; connective tissue cancer;cancer of the digestive system; endometrial cancer; esophageal cancer;eye cancer; cancer of the head and neck; gastric cancer (includinggastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma;intra-epithelial neoplasm; kidney or renal cancer; larynx cancer;leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer,non-small cell lung cancer, adenocarcinoma of the lung, and squamouscarcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavitycancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreaticcancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectalcancer; cancer of the respiratory system; salivary gland carcinoma;sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicularcancer; thyroid cancer; uterine or endometrial cancer; cancer of theurinary system; vulval cancer; lymphoma including Hodgkin’s andnon-Hodgkin’s lymphoma, as well as B-cell lymphoma (including lowgrade/follicular non-Hodgkin’s lymphoma (NHL); small lymphocytic (SL)NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL;high grade immunoblastic NHL; high grade lymphoblastic NHL; high gradesmall non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma;AIDS-related lymphoma; and Waldenstrom’s Macroglobulinemia; chroniclymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairycell leukemia; chronic myeloblastic leukemia; as well as othercarcinomas and sarcomas; and post-transplant lymphoproliferativedisorder (PTLD), as well as abnormal vascular proliferation associatedwith phakomatoses, edema (such as that associated with brain tumors),and Meigs’ syndrome.

This document therefore also provides compositions containing a vectoror a tumor cell or virus particle containing a vector encoding asecreted gp96-Ig fusion polypeptide and a T cell costimulatory fusionpolypeptide as described herein, in combination with a physiologicallyand pharmaceutically acceptable carrier. The physiologically andpharmaceutically acceptable carrier can include any of the well-knowncomponents useful for immunization. The carrier can facilitate orenhance an immune response to an antigen administered in a vaccine. Thecell formulations can contain buffers to maintain a preferred pH range,salts or other components that present an antigen to an individual in acomposition that stimulates an immune response to the antigen. Thephysiologically acceptable carrier also can contain one or moreadjuvants that enhance the immune response to an antigen.Pharmaceutically acceptable carriers include, for example,pharmaceutically acceptable solvents, suspending agents, or any otherpharmacologically inert vehicles for delivering compounds to a subject.Pharmaceutically acceptable carriers can be liquid or solid, and can beselected with the planned manner of administration in mind so as toprovide for the desired bulk, consistency, and other pertinent transportand chemical properties, when combined with one or more therapeuticcompounds and any other components of a given pharmaceuticalcomposition. Typical pharmaceutically acceptable carriers include,without limitation: water, saline solution, binding agents (e.g.,polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g.,lactose or dextrose and other sugars, gelatin, or calcium sulfate),lubricants (e.g., starch, polyethylene glycol, or sodium acetate),disintegrates (e.g., starch or sodium starch glycolate), and wettingagents (e.g., sodium lauryl sulfate). Compositions can be formulated forsubcutaneous, intramuscular, or intradermal administration, or in anymanner acceptable for immunization.

An adjuvant refers to a substance which, when added to an immunogenicagent such as a tumor cell expressing secreted vaccine protein (e.g.,gp96-Ig) and, optionally, T cell costimulatory fusion polypeptides,nonspecifically enhances or potentiates an immune response to the agentin the recipient host upon exposure to the mixture. Adjuvants caninclude, for example, oil-in-water emulsions, water-in oil emulsions,alum (aluminum salts), liposomes and microparticles, such as,polysytrene, starch, polyphosphazene and polylactide/polyglycosides.

Adjuvants can also include, for example, squalene mixtures (SAF-I),muramyl peptide, saponin derivatives, mycobacterium cell wallpreparations, monophosphoryl lipid A, mycolic acid derivatives, nonionicblock copolymer surfactants, Quil A, cholera toxin B subunit,polyphosphazene and derivatives, and immunostimulating complexes(ISCOMs) such as those described by Takahashi et al., Nature 1990,344:873-875. For veterinary use and for production of antibodies inanimals, mitogenic components of Freund’s adjuvant (both complete andincomplete) can be used. In humans, Incomplete Freund’s Adjuvant (IFA)is a useful adjuvant. Various appropriate adjuvants are well known inthe art (see, for example, Warren and Chedid, CRC Critical Reviews inImmunology 1988, 8:83; and Allison and Byars, in Vaccines: NewApproaches to Immunological Problems, 1992, Ellis, ed.,Butterworth-Heinemann, Boston). Additional adjuvants include, forexample, bacille Calmett-Guerin (BCG), DETOX (containing cell wallskeleton of Mycobacterium phlei (CWS) and monophosphoryl lipid A fromSalmonella minnesota (MPL)), and the like (see, for example, Hoover etal., J Clin Oncol 1993, 11:390; and Woodlock et al., J Immunother 1999,22:251-259).

In some embodiments, a vector can be administered to a subject, directlyor indirectly (e.g., within a biological cell), one or more times (e.g.,once, twice, two to four times, three to five times, five to eighttimes, six to ten times, eight to 12 times, or more than 12 times). Avector or biological cell as provided herein can be administered one ormore times per day, one or more times per week, every other week, one ormore times per month, once every two to three months, once every threeto six months, or once every six to 12 months. A vector can beadministered over any suitable period of time, such as a period fromabout 1 day to about 12 months. In some embodiments, for example, theperiod of administration can be from about 1 day to 90 days; from about1 day to 60 days; from about 1 day to 30 days; from about 1 day to 20days; from about 1 day to 10 days; from about 1 day to 7 days. In someembodiments, the period of administration can be from about 1 week to 50weeks; from about 1 week to 50 weeks; from about 1 week to 40 weeks;from about 1 week to 30 weeks; from about 1 week to 24 weeks; from about1 week to 20 weeks; from about 1 week to 16 weeks; from about 1 week to12 weeks; from about 1 week to 8 weeks; from about 1 week to 4 weeks;from about 1 week to 3 weeks; from about 1 week to 2 weeks; from about 2weeks to 3 weeks; from about 2 weeks to 4 weeks; from about 2 weeks to 6weeks; from about 2 weeks to 8 weeks; from about 3 weeks to 8 weeks;from about 3 weeks to 12 weeks; or from about 4 weeks to 20 weeks.

In some embodiments, after an initial dose (sometimes referred to as a“priming” dose) of a vector has been administered and a maximalantigen-specific immune response has been achieved, one or more boostingdoses of a vector as provided herein can be administered. For example, aboosting dose can be administered about 10 to 30 days, about 15 to 35days, about 20 to 40 days, about 25 to 45 days, or about 30 to 50 daysafter a priming dose.

In some embodiments, the methods provided herein can be used forcontrolling solid tumor growth (e.g., breast, prostate, melanoma, renal,colon, or cervical tumor growth) and/or metastasis. The methods caninclude administering an effective amount of an expression vector asdescribed herein to a subject in need thereof. In some embodiments, thesubject is a mammal (e.g., a human).

The vectors and methods provided herein can be useful for stimulating animmune response against a tumor. Such immune response is useful intreating or alleviating a sign or symptom associated with the tumor. Asused herein, by “treating” is meant reducing, preventing, and/orreversing the symptoms in the individual to which a vector as describedherein has been administered, as compared to the symptoms of anindividual not being treated. A practitioner will appreciate that themethods described herein are to be used in concomitance with continuousclinical evaluations by a skilled practitioner (physician orveterinarian) to determine subsequent therapy. Such evaluations will aidand inform in evaluating whether to increase, reduce, or continue aparticular treatment dose, mode of administration, etc.

The methods provided herein can thus be used to treat a tumor,including, for example, a cancer. The methods can be used, for example,to inhibit the growth of a tumor by preventing further tumor growth, byslowing tumor growth, or by causing tumor regression. Thus, the methodscan be used, for example, to treat a cancer such as a lung cancer. Itwill be understood that the subject to which a compound is administeredneed not suffer from a specific traumatic state. Indeed, the vectorsdescribed herein may be administered prophylactically, prior todevelopment of symptoms (e.g., a patient in remission from cancer). Theterms “therapeutic” and “therapeutically,” and permutations of theseterms, are used to encompass therapeutic, palliative, and prophylacticuses. Thus, as used herein, by “treating or alleviating the symptoms” ismeant reducing, preventing, and/or reversing the symptoms of theindividual to which a therapeutically effective amount of a compositionhas been administered, as compared to the symptoms of an individualreceiving no such administration.

As used herein, the terms “effective amount” and “therapeuticallyeffective amount” refer to an amount sufficient to provide the desiredtherapeutic (e.g., anti-cancer, anti-tumor, or anti-infection) effect ina subject (e.g., a human diagnosed as having cancer or an infection).Anti-tumor and anti-cancer effects include, without limitation,modulation of tumor growth (e.g., tumor growth delay), tumor size, ormetastasis, the reduction of toxicity and side effects associated with aparticular anti-cancer agent, the amelioration or minimization of theclinical impairment or symptoms of cancer, extending the survival of thesubject beyond that which would otherwise be expected in the absence ofsuch treatment, and the prevention of tumor growth in an animal lackingtumor formation prior to administration, i.e., prophylacticadministration. In some embodiments, administration of an effectiveamount of a vector or a composition, cell, or virus particle containingthe vector can increase the activation or proliferation of tumor antigenspecific T cells in a subject. For example, the activation orproliferation of tumor antigen specific T cells in the subject can be isincreased by at least 10 percent (e.g., at least 25 percent, at least 50percent, or at least 75 percent) as compared to the level of activationor proliferation of tumor antigen specific T cells in the subject priorto the administration.

One of skill will appreciate that an effective amount of a vector may belowered or increased by fine tuning and/or by administering more thanone dose (e.g., by concomitant administration of two differentgenetically modified tumor cells containing the vector), or byadministering a vector with another agent (e.g., an antagonist of PD-1)to enhance the therapeutic effect (e.g., synergistically). This documenttherefore provides a method for tailoring the administration/treatmentto the particular exigencies specific to a given mammal. Therapeuticallyeffective amounts can be determined by, for example, starting atrelatively low amounts and using step-wise increments with concurrentevaluation of beneficial effects. The methods provided herein thus canbe used alone or in combination with other well-known tumor therapies,to treat a patient having a tumor. One skilled in the art will readilyunderstand advantageous uses of the vectors and methods provided herein,for example, in prolonging the life expectancy of a cancer patientand/or improving the quality of life of a cancer patient (e.g., a lungcancer patient).

Combination Therapies and Conjugation

In some embodiments, the invention provides for methods that furthercomprise administering an additional agent to a subject. In someembodiments, the invention pertains to co-administration and/orco-formulation.

In some embodiments, administration of vaccine protein (e.g., gp96-Ig)acts synergistically when co-administered with another agent and isadministered at doses that are lower than the doses commonly employedwhen such agents are used as monotherapy.

In some embodiments, administration of vaccine protein (e.g., gp96-Ig)and one or more costimulatory molecules act synergistically whenco-administered with another agent and is administered at doses that arelower than the doses commonly employed when such agents are used asmonotherapy.

In some embodiments, inclusive of, without limitation, cancerapplications, the present invention pertains to chemotherapeutic agentsas additional agents. Examples of chemotherapeutic agents include, butare not limited to, alkylating agents such as thiotepa and CYTOXANcyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan andpiposulfan; aziridines such as benzodopa, carboquone, meturedopa, anduredopa; ethylenimines and methylamelamines including altretamine,triethylenemelamine, trietylenephosphoramide,triethiylenethiophosphoramide and trimethylolomelamine; acetogenins(e.g., bullatacin and bullatacinone); a camptothecin (including thesynthetic analogue topotecan); bryostatin; cally statin; CC-1065(including its adozelesin, carzelesin and bizelesin syntheticanalogues); cryptophycins (e.g., cryptophycin 1 and cryptophycin 8);dolastatin; duocarmycin (including the synthetic analogues, KW-2189 andCB 1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin;nitrogen mustards such as chlorambucil, chlornaphazine,cholophosphamide, estramustine, ifosfamide, mechlorethamine,mechlorethamine oxide hydrochloride, melphalan, novembichin,phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureassuch as carmustine, chlorozotocin, fotemustine, lomustine, nimustine,and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.,calicheamicin, especially calicheamicin gammall and calicheamicinomegall (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994));dynemicin, including dynemicin A; bisphosphonates, such as clodronate;an esperamicin; as well as neocarzinostatin chromophore and relatedchromoprotein enediyne antibiotic chromophores), aclacinomysins,actinomycin, authramycin, azaserine, bleomycins, cactinomycin,carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin,daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCINdoxorubicin (including morpholino- doxorubicin,cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin,mitomycins such as mitomycin C, mycophenolic acid, nogalamycin,olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,zinostatin, zorubicin; anti-metabolites such as methotrexate and5-fluorouracil (5-FU); folic acid analogues such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as minoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; demecolcine; diaziquone;elformithine; elliptinium acetate; an epothilone; etoglucid; galliumnitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such asmaytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharidecomplex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;sizofuran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″trichlorotriethylamine; trichothecenes (e.g., T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C″); cyclophosphamide; thiotepa; taxoids, e.g., TAXOLpaclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANECremophor-free, albumin-engineered nanoparticle formulation ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, 111.), andTAXOTERE doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil;GEMZAR gemcitabine; 6-thioguanine; mercaptopurine; methotrexate;platinum analogs such as cisplatin, oxaliplatin and carboplatin;vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone;vincristine; NAVELBINE. vinorelbine; novantrone; teniposide; edatrexate;daunomycin; aminopterin; xeloda; ibandronate; irinotecan (Camptosar,CPT-11) (including the treatment regimen of irinotecan with 5-FU andleucovorin); topoisomerase inhibitor RFS 2000; difluoromethylornithine(DMFO); retinoids such as retinoic acid; capecitabine; combretastatin;leucovorin (LV); oxaliplatin, including the oxaliplatin treatmentregimen (FOLFOX); lapatinib (TYKERB); inhibitors of PKC-α, Raf, H-Ras,EGFR (e.g., erlotinib (Tarceva)) and VEGF-A that reduce cellproliferation and pharmaceutically acceptable salts, acids orderivatives of any of the above. In addition, the methods of treatmentcan further include the use of radiation. In addition, the methods oftreatment can further include the use of photodynamic therapy.

Other additional agents are described elsewhere herein, including theblocking antibodies targeted to an immune “checkpoint” molecules.

Subjects And/or Animals

The methods described herein are intended for use with any subject thatmay experience the benefits of these methods. Thus, “subjects,”“patients,” and “individuals” (used interchangeably) include humans aswell as non-human subjects, particularly domesticated animals.

In some embodiments, the subject and/or animal is a mammal, e.g., ahuman, mouse, rat, guinea pig, dog, cat, horse, cow, pig, rabbit, sheep,or non-human primate, such as a monkey, chimpanzee, or baboon. In otherembodiments, the subject and/or animal is a non-mammal, such, forexample, a zebrafish. In some embodiments, the subject and/or animal maycomprise fluorescently-tagged cells (with e.g., GFP). In someembodiments, the subject and/or animal is a transgenic animal comprisinga fluorescent cell.

In some embodiments, the subject and/or animal is a human. In someembodiments, the human is a pediatric human. In other embodiments, thehuman is an adult human. In other embodiments, the human is a geriatrichuman. In other embodiments, the human may be referred to as a patient.

In certain embodiments, the human has an age in a range of from about 0months to about 6 months old, from about 6 to about 12 months old, fromabout 6 to about 18 months old, from about 18 to about 36 months old,from about 1 to about 5 years old, from about 5 to about 10 years old,from about 10 to about 15 years old, from about 15 to about 20 yearsold, from about 20 to about 25 years old, from about 25 to about 30years old, from about 30 to about 35 years old, from about 35 to about40 years old, from about 40 to about 45 years old, from about 45 toabout 50 years old, from about 50 to about 55 years old, from about 55to about 60 years old, from about 60 to about 65 years old, from about65 to about 70 years old, from about 70 to about 75 years old, fromabout 75 to about 80 years old, from about 80 to about 85 years old,from about 85 to about 90 years old, from about 90 to about 95 years oldor from about 95 to about 100 years old.

In other embodiments, the subject is a non-human animal, and thereforethe invention pertains to veterinary use. In a specific embodiment, thenon-human animal is a household pet. In another specific embodiment, thenon-human animal is a livestock animal. In certain embodiments, thesubject is a human cancer patient that cannot receive chemotherapy,e.g., the patient is unresponsive to chemotherapy or too ill to have asuitable therapeutic window for chemotherapy (e.g., experiencing toomany dose- or regimen-limiting side effects). In certain embodiments,the subject is a human cancer patient having advanced and/or metastaticdisease.

As used herein, an “allogeneic cell” refers to a cell that is notderived from the individual to which the cell is to be administered,that is, has a different genetic constitution than the individual. Anallogeneic cell is generally obtained from the same species as theindividual to which the cell is to be administered. For example, theallogeneic cell can be a human cell, as disclosed herein, foradministering to a human patient such as a cancer patient. As usedherein, an “allogeneic tumor cell” refers to a tumor cell that is notderived from the individual to which the allogeneic cell is to beadministered. Generally, the allogeneic tumor cell expresses one or moretumor antigens that can stimulate an immune response against a tumor inan individual to which the cell is to be administered. As used herein,an “allogeneic cancer cell,” for example, a lung cancer cell, refers toa cancer cell that is not derived from the individual to which theallogeneic cell is to be administered.

As used herein, a “genetically modified cell” refers to a cell that hasbeen genetically modified to express an exogenous nucleic acid, forexample, by transfection or transduction.

Technical and scientific terms used herein have the meaning commonlyunderstood by one of skill in the art to which the present inventionpertains, unless otherwise defined.

As used herein, the singular forms “a,” “an” and “the” specifically alsoencompass the plural forms of the terms to which they refer, unless thecontent clearly dictates otherwise. As used herein, unless specificallyindicated otherwise, the word “or “is used in the “inclusive” sense of“and/or” and not the “exclusive” sense of either/or.” In thespecification and the appended claims, the singular forms include pluralreferents unless the context clearly dictates otherwise.

The term “about” is used herein to mean approximately, in the region of,roughly, or around. When the term “about” is used in conjunction with anumerical range, it modifies that range by extending the boundariesabove and below the numerical values set forth. In general, the term“about” is used herein to modify a numerical value above and below thestated value by a variance of 20%. As used in this specification,whether in a transitional phrase or in the body of the claim, the terms“comprise (s)” and “comprising” are to be interpreted as having anopen-ended meaning. That is, the terms are to be interpretedsynonymously with the phrases “having at least” or “including at least”.When used in the context of a process, the term “comprising” means thatthe process includes at least the recited steps, but may includeadditional steps. When used in the context of a compound or composition,the term “comprising” means that the compound or composition includes atleast the recited features or components, but may also includeadditional features or components.

The invention will be further described in the following examples, whichdo not limit the scope of the invention described in the claims.

EXAMPLES Example 1: Combined Intratumoral Electroporation and AllogeneicVaccination of GP96-Ig/Fc-OX40L Stimulates CD8+ T Cell Cross Priming toTumor-Specific Neoantigens and Enhances Anti-Tumor Response

FIG. 1 shows the experimental design of the present Example.

FIG. 2A shows 50 µg of a bovine papilloma virus plasmid vectorco-expressing Gp96.lg and Fc-OX40L (~12 kb) was injected intosubcutaneous B16.F10 tumors (n=6 per group) and electroporated under twoseparate parameters. Three days following electroporation the level ofFIG. 2B: tumor cell associated Gp96.lg mRNA and FIG. 2C: tumor lysateassociated OX40L protein was quantified by qPCR and ELISA, respectively.

FIG. 3A: C57BL/6 albino mice were adoptively transferred with OT1-GFPcells and inoculated with two B16.F10-ova tumors on opposing rearflanks. Only the primary tumor was electroporated with either saline (EPonly) or Gp96.Ig/Fc-OX40L DNA. (FIG. 3B and FIG. 3C) Growth of theprimary/treated and contralateral/untreated tumor was monitored over 40days. FIG. 3D: The percentage of CD8+ OT1-GFP cells in peripheral bloodwas monitored over time by flow cytometry. FIG. 3E: Phenotypic analysisof ova-antigen specific CD8+ T cells on day 11 following EP by flowcytometry reveals increased numbers of CD127+/KLRG- memory precursorcells in mice EP’d with Gp96.lg/Fc-OX40L. FIG. 3F: Overall survival ofB16.F10 melanoma bearing mice EP’d with saline or Gp96.Ig/Fc-OX40L. *indicates p<0.05. Statistical significance was determined by studentt-test and Mantel-Cox test.

FIG. 4A: C57BL/6 mice bearing primary and contralateral B16.F10-ovatumors on opposing rear flanks were EP’d only in their primary tumoronce with Gp96.Ig/Fc-OX40L DNA alone or in combination with IPadministration of a triple dose of mitomycin-treated B16.F10-ovaallogeneic vaccine cells secreting Gp96.lg and Fc-OX40L. (FIG. 4B, FIG.4C and FIG. 4D) Growth of the primary/treated andcontralateral/untreated tumors and survival was monitored over 30 days.(FIG. 4E and FIG. 4F) A subgroup of mice from each group (n=6) wassacrificed on day 6 following EP, tumors were excised, weighed andenzymatically dissociated to isolate tumor cells and tumor infiltratinglymphocytes (TIL). Isolated cells were stained for SIINFEKL tetramer+CD8+ T cells (representing Ova antigen-specific CD8+ T cells) andquantified by flow cytometry. Cells were negatively gated to excludecells positive for Nk1.1, Gr-1, CD11b and CD11c and subsequentlypre-gated on CD3+. * indicates p<0.05. Statistical significance wasdetermined by either student t-test, ANOVA or Mantel-Cox test whereappropriate.

This combination approach led to an increased expansion ofantigen-specific CD8 T cells in tumors and in the peripheral bloodcompared to the individual monotherapies, which increased anti-tumorresponse rates. These findings suggest that a combination approach ofallogeneic vaccination and in situ tumor EP of Gp96-Ig/Fc-OX40L may havesignificant benefit in eliciting a potent immune response inless-immunogenic tumors.

In vivo EP of DNA-based gp96.Ig/Fc-OX40L into B16 melanoma tumorsresulted in CD8 T cell cross priming, increased antigen-specificprecursor memory T cells and delayed tumor progression of treated anddistal, untreated tumors.

Combining in vivo electroporation of gp96.Ig/Fc-OX40L DNA with anallogeneic vaccine secreting the same therapeutic agents enhanced theefficacy of treating B16 melanoma tumors due to improved CD8 T cellcross priming

This study provided, inter alia, proof-of-concept for pairinggp96.Ig-based vaccines with intratumoral gp96 therapies

OTHER EMBODIMENTS

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

The content of any individual section may be equally applicable to allsections.

INCORPORATION BY REFERENCE

All patents and publications referenced herein are hereby incorporatedby reference in their entireties.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application. Nothingherein is to be construed as an admission that the present invention isnot entitled to antedate such publication by virtue of prior invention.

As used herein, all headings are simply for organization and are notintended to limit the disclosure in any way.

1. A method for treating a tumor in a subject in need thereof,comprising intratumorally delivering an effective amount of acomposition comprising an expression vector that comprises a firstnucleotide sequence encoding a secretable qp96-immunoqlobulin (qp96-lq)fusion protein which lacks the qp96 KDEL (SEQ ID NO: 3) sequence, and asecond nucleotide sequence encoding a T cell costimulatory fusionprotein.
 2. The method of claim 1, wherein the intratumoral delivery isin vivo by injection.
 3. The method of claim 2, further comprisingadministering to the subject effective amount of a biological cellcomprising an expression vector that comprises a first nucleotidesequence encoding a secretable qp96-lq fusion protein which lacks theqp96 KDEL (SEQ ID NO: 3) sequence, and a second nucleotide sequenceencoding a T cell costimulatory fusion protein, wherein the T cellcostimulatory fusion protein enhances activation of antigen-specific Tcells when administered to the subject.
 4. The method of claim 1,wherein the method elicits a potent immune response in aless-immunogenic tumor characterized by reduced inflammation compared toan untreated tumor.
 5. The method of claim 1, wherein the methodenhances CD4+/CD8+T cell cross-priming to tumor neo-antigens.
 6. Themethod of claim 1, wherein the vector is a mammalian expression vector.7. (canceled)
 8. The method of claim 1, wherein the gp96-Ig fusionprotein comprises an Iq portion comprising the Fc region of human IgG1,IgG2, IgG3, IgG4, IgM, IgA, or IgE.
 9. The method of claim 1, whereinthe T cell costimulatory fusion protein is OX40L-Ig, or a portionthereof that binds to OX40, or ICOSL-Ig, or a portion thereof that bindsto ICOS, or 4-1BBL-Ig, or a portion thereof that binds to 4-1BBR, orTL1A-Ig, or a portion thereof that binds to TNFRSF25, or GITRL-Ig, or aportion thereof that binds to GITR, or CD40L-Ig, or a portion thereofthat binds to CD40, or CD70-Ig, or a portion thereof that binds to CD27.10-15. (canceled)
 16. The method of claim 9, wherein the T cellcostimulatory fusion protein comprises an Ig portion comprising the Fcregion of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, or IgE.
 17. The methodof claim 1, wherein the expression vector comprises DNA or RNA. 18.(canceled)
 19. The method of claim 1, wherein the expression vector isincorporated into a virus or virus-like particle.
 20. (canceled)
 21. Themethod of claim 1, wherein the subject is a human cancer patient. 22.The method of claim 21, wherein delivery increases the activation orproliferation of tumor antigen specific T cells in the patient.
 23. Themethod of claim 22, wherein the activation or proliferation of tumorantigen specific T cells in the patient is increased by at least 25percent as compared to the level of activation or proliferation of tumorantigen specific T cells in the patient prior to the administration. 24.The method of claim 1, comprising administering in combination with anagent that inhibits immunosuppressive molecules produced by tumor cells.25. The method of claim 24, wherein the agent that inhibitsimmunosuppressive molecules is an antibody against PD-1.